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ENHANCING CELL THERAPY FOR ISCHEMIC CARDIOMYOPATHY 
 
Michael J. Book 
May 13, 2017 
Cardiac cell therapy using cardiac mesenchymal cells (CMC) significantly reduces 
ventricular dysfunction in patients with ischemic cardiomyopathy. Despite the 
improvement in function, a modest number of CMCs survive in the heart post-
transplantation. In this study, we sought to improve the survival and retention of 
transplanted CMCs to prolong the therapeutic benefits afforded by cardiac cell therapy. To 
do this, we targeted the enzyme telomerase (TERT), known to be active in some highly 
proliferating cells (e.g. germ, stem). TERT is responsible for preventing telomere attrition, 
thereby allowing continued proliferation. TERT has also been shown to be protective, 
improve cell migration and stimulate angiogenesis. These actions make the expression of 
TERT an ideal target. In this study, we overexpressed TERT in CMCs using a lentiviral 
vector. While TERT overexpression immortalized other cell types, in our hands TERT 
overexpression did not result in increasing CMC lifespan. Also, overexpression did not 
improve migration or oxidative stress resistance in CMCs. While TERT is commonly 
believed to be silent in somatic cells, it has been shown to be detected in the heart. So, we 
also attempted to exhaustively identify endogenous TERT expression in CMCs, but 
expression in CMCs could not be detected. To go a step further, we then attempted to 
 vi 
identify TERT expression in a highly proliferative subpopulation of clonogenic CMCs. 
Clonogenicity is a known characteristic of TERT expressing cells, but we were unable to 
detect TERT in clonal CMCs. Although we did not find TERT expression and 
overexpression was fruitless, we did identify more resilient, proliferative CMCs using the 
cloning technique. We successfully identified CMC clones with differential stress 
resistance, paracrine stimulation and growth rate that appear morphologically and 
genetically distinct. Furthermore, we found that transplanting clonogenic CMCs with 
reduced stress resistance does not ameliorate cardiac function in chronically infarcted rat 
hearts. However, transplanting unsorted CMCs caused a modest, but significant, 
improvement of cardiac function. These results suggest that subpopulations exist within 
the unsorted CMCs that provide no therapeutic benefit. It also suggests a correlation 
between in vitro stress resistance and reduction in ventricular impairment. 
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 The heart is a four-chambered organ made up of two atria and two ventricles. The 
right side of the heart is the low-pressure pump that is responsible for pumping blood 
through the pulmonary vasculature to oxygenate the blood [1]. The left side of the heart is 
the high-pressure pump that is responsible for pumping the oxygenated blood to the 
systemic circulation, including the heart itself. Specifically, the heart provides most of the 
nutrients to itself by blood passing through the coronary circulation. The coronary 
circulation is divided into the right main coronary artery and left main coronary artery, 
which is further divided into left anterior descending (LAD) and circumflex branches. 
Both the left and right coronary arteries emanate from the base of the aorta and lie on the 
surface of the heart with the smaller vasculature penetrating the muscular walls of the 
heart. The left main coronary artery supplies the blood to the anterior and left lateral 
portion of the heart whereas the right main coronary artery supplies blood to the right 
ventricle and the posterior left ventricle. In the resting person, about 5% of the total 
cardiac output flows through the coronary vasculature. 
 In the normal, resting state, the heart consumes about 70% of the oxygen supplied 
by the blood in the coronary arteries. This leaves very little oxygen reserve if there is an 
increased demand. This means that flow of blood through the heart is coupled with 
oxygen demand and metabolism of the heart. In the normal heart, as activity increases 
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and demand for oxygen increases there is almost a proportionate increase in coronary 
blood flow [1].  It is easy to understand how a reduction of blood flow to the heart tissue 
could have devastating effects. 
 
Pathological Heart  
Heart disease is the leading cause of death claiming 25% of all deaths in the U.S. 
[2, 3], more lives than all forms of cancer combined. The magnitude of burden placed on 
the globe is tremendous. With the rise in prevalence of poor diet, obesity, sedentary 
lifestyle, diabetes and excessive alcohol use, the problem will continue to escalate. The 
most common, coronary artery disease, costs the U.S. over $100 billion and results in over 
700,000 heart attacks each year. That equates to someone having a heart attack about every 
34 seconds. A heart attack occurs when the flow of oxygen-rich blood to a section of the 
heart becomes blocked [4].  
The blockage begins as a buildup in the walls of the coronary arteries resulting in 
thickening and stiffening of the arterial walls [1]. When the arterial endothelial cells 
encounter one or a combination of a diverse variety of bacterial products or risk factors, 
vasoconstrictor hormones, glycoxidation products, or proinflammatory cytokines, the 
endothelial cells modify the expression of adhesion molecules [5]. Adhesion molecules, 
such as VCAM1, promote the sticking of monocytes to the inner surface of the arterial wall 
causing the monocytes to roll along the endothelial wall and transmigrate at the site of the 
insult [6]. Monocytes begin to cross the endothelial wall, enter the intima layer of the 
coronary vessel and differentiate into macrophages. The macrophages release factors that 
stimulate inflammation; smooth muscle cell migration and proliferation from the tunica 
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media to the tunica intima; and fibrosis [5]. The macrophages also digest the accumulated 
lipoproteins and turn into what is commonly called “foam cells” which aggregate in the 
intima of the vessel forming a lipid-rich necrotic lesion [7]. The preliminary lesion is called 
a intima xanthoma eventually becoming a fibroatheroma [6].   
Over time, the lesion will cause either positive or negative remodeling of the vessel. 
Positive remodeling is an outward compensatory remodeling that maintains the size of the 
lumen whereas negative remodeling results in shrinkage of the diameter of the lumen, 
reducing the flow of blood [8]. Sometimes the negative remodeling can become so severe 
that it totally occludes the vessel. Covering the plaque of the atheroma in the damaged 
vessel is a fibrous cap that can vary in thickness. The fibrous cap covered plaque can be 
referred to as a thick- or thin-cap fibroatheroma. Depending on the fragility of the fibrous 
cap, the level of stenosis and the lipid core and plaque dimensions, the lesion can weaken 
the vessel and result in the rupture of the plaque of the fibroatheroma forming a thrombus. 
Plaque ruptures occur in a lesion with a large necrotic core with an overlying thin disrupted 
fibrous cap, measuring <65 µm and is heavily infiltrated by macrophages and T-
lymphocytes [6]. Atherosclerotic plaque rupture and thrombosis is the primary cause of 
most acute coronary syndromes and sudden coronary death [6]. The thrombus causes a 
sudden blockage of blood flow to the area beyond the occlusion resulting in ischemia 
referred to as an infarct precipitating what is known as a myocardial infarction. If blood 
flow is not restored quickly there is a perfusion imbalance between the supply and demand, 
causing myocardial tissue death [4, 9].   
The myocardium consists of 3 primary components: myocytes, extracellular matrix 
and capillary microcirculation [10]. The myocytes are the contractile cells of the heart that 
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are supported by the stress-tolerant extracellular matrix which maintains the spatial 
relationship between the myofilaments and the microcirculation. The framework of the 
extracellular matrix, consisting primarily of collagen, helps to optimize the force generated 
by the myocytes and distribute it across the tissue. After the onset of ischemia, cell death 
isn’t immediate [9]. There is finite amount of time before cell death leading to complete 
necrosis causing a loss of myocardium and an abrupt change of the loading conditions of 
the heart. To accommodate the change, there is a remodeling of the heart that is divided 
into early and late stage remodeling [10].  
Occurring within hours of the infarct, early stage remodeling is the expansion of 
the infarct [10]. This expansion is highlighted with myocyte death, intermyoctye collagen 
degradation and a thinning of the myocardial wall. Wall thinning leads to the deformation 
and dilation of the ventricle, as seen in Figure 1, and an increase in systolic and diastolic 
 
Figure 1 - The phenotypic change of the heart after an infarct. From the left, an occlusion 
results in blockage of blood flow to the apical region of the heart resulting in an infarct. In the 
middle, early stage remodeling expands the infarct with increased tissue necrosis. As 
myocardium is lost, on the right, wall thinning causes deformation & dilation of the ventricle. 
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stress. Infarct expansion causes the deformation of the border zone and remote 
myocardium, which alters Frank/Starling relations and augments shortening [10]. The 
increase in stress stimulates a compensatory hypertrophy in the non-infarcted region of the 
heart to preserve stroke volume leading into late stage remodeling. In late stage remodeling, 
a collagen scar is formed to attenuate further deformation of the ventricle and additional 
myocyte hypertrophy occurs to adapt to the increased load. This pathological state is 
referred to as ischemic cardiomyopathy, the most common cause of heart failure [11].  
 
Treatment of Ischemic Cardiomyopathy 
The treatment of ischemic cardiomyopathy has continued to evolve as our 
understanding of cardiac physiology has progressed. Prior to the 1980s, treatment of heart 
failure was largely non-pharmacologic with treatments focusing on changes or limitations 
of lifestyle. Then a variety of pharmacologic agents began to be introduced including 
vasodilators, angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, 
beta-blockers and many others which primarily acted as a way to manage heart failure [12]. 
Advances in technology introduced several devices to manage the disease including stents, 
defibrillators, pacemakers, left ventricular assist devices and even a total artificial heart. 
However, in many cases these devices simply act as a bridge to heart transplant. Each of 
these treatments have their own problems, but none of them address the problem of loss of 
cardiac function.   
It was previously believed that the adult human heart was unable to repair itself 
because it was terminally differentiated  [13]. It was believed that cardiomyocytes were 
unable to reenter the cell cycle, synthesize DNA and undergo mitotic division [14]. The 
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general contention was that in neonatal life cardiomyocytes lose their ability to proliferate 
and progress to hypertrophic growth [15]. This belief was supported by the lack of myocyte 
regeneration following a cardiac insult and the low frequency of cardiac tumors. It was 
later found that mitotic cells could occasionally be detected in the pathologic heart, but at 
the time it was thought to be irrelevant [14]. It was then discovered that cell death occurs 
with age in the human heart inferring a turnover of cells [16] and subsequently found that 
cardiomyocytes can re-enter the cell cycle and could be detected in the heart undergoing 
mitosis [14]. 
This lead to the discovery of cardiac cells that have a regenerative capacity that 
could be used for cardiac cell therapy [17]. Cardiac cells used for therapy have been 
identified with antigenic selection (e.g. c-kit) [18] or by cardiosphere-expansion [19].  Our 
group performed the first Phase I trial utilizing antigenic-selected c-kit-positive cardiac 
cells called the SCIPIO trial [18]. In this trial, we collaborated with Dr. Piero Anversa at 
Harvard University who isolated c-kit-positive adult cardiac cells from the patient’s heart. 
C-kit is a receptor tyrosine kinase that is known to be stimulated by Stem Cell Factor (SCF) 
to activate several different signaling pathways [20]. It has been shown to be important in 
regulating proliferation, survival and vital functions in hematopoietic cells.  
In the SCIPIO trial, c-kit-positive cardiac cells were isolated from and transplanted 
back in to the damaged heart of patients with ischemic cardiomyopathy using a catheter in 
combination with a balloon occluder. It was found that cardiac cell therapy using c-kit 
sorted cardiac cells resulted in a significant sustained improvement of ventricular function 
and quality of life [18]. However, it has now been discovered that sub-selection of cardiac 
cells for cell therapy may not be required to achieve ventricular functional improvement. 
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Cardiac cells harvested directly from the initial outgrowth from cardiac tissue have shown 
similar therapeutic benefits [21]. These cardiac cells, deemed as cardiac 
mesenchymal/stromal cells (CMC), are largely made up of mesenchymal cells and 
fibroblasts [21, 22]. This simplified method alleviates the need for arduous selection 
processes and greatly increases the efficiency of isolation of cardiac cells for cell therapy, 
but also indicates the possibility that an optimal sub-population of cardiac cells has yet to 
be defined. 
 Regardless of the cell type used for cardiac cell therapy, currently only a modest 
number of cells survive transplantation and the precise mechanism of ventricular functional 
improvement is unknown. In mice with a chronic MI, our group found that only ~2% of 
the successfully transplanted cardiac cells survive after 35-days by using quantitative RT-
PCR to calculate the number of cells that were retained in the heart [23]. Thus far, data 
suggests paracrine mechanisms have a greater importance due to cells exhibiting poor 
survival and differentiation when transplanted in the infarcted heart [22-24]. A recent study 
further supported this by revealing that co-transplantation of CMCs with circulatory 
angiogenic cells resulted in a greater ventricular functional improvement without an 
increase in cell retention compared to CMCs alone [25].  It is believed that the synergy of 
these individual therapies was mediated by complimentary paracrine profiles. 
Unfortunately, identifying the precise combination of cells or paracrine factors that provide 
this therapeutic phenomenon would result in chasing an endless number of possibilities.  
However, it has also been shown that prolonging the retention of transplanted cells 
in the infarcted heart results in greater ventricular functional improvement as well. Dr. 
Mark Sussman’s group overexpressed Pim-1 kinase in cardiac progenitor cells [26]. 
 8 
Overexpression of Pim-1 kinase in cardiac progenitor cells resulted in a significantly 
greater number of cells retained in the heart post-transplantation and an improvement in 
left ventricular function compared to unaltered cardiac progenitor cells. This suggests that 
CMCs can be optimized to increase therapeutic efficacy. Furthermore, the poor survival of 
the transplanted CMCs could indicate that a therapeutic sub-population exists that better 
survives transplantation into the ischemic heart. In this study, we sought to identify 
“superior” CMCs with elevated survival and proliferation characteristics to prolong the 
beneficial effects resulting from cardiac cell therapy which we believe will result in a 
greater functional improvement.  
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CHAPTER II 
CMCs EXPRESSING TELOMERASE FOR CELL THERAPY  
Introduction 
Ischemic cardiomyopathy is a heart condition that leads to cardiomyocyte loss, scar 
formation and heart failure [11], one of the world’s leading causes of death. In recent years, 
treatment of ischemic cardiomyopathy with cardiac cell therapy has had salutary, albeit 
modest, therapeutic benefits [18]. Regardless of the selected cells used for transplantation 
into the damaged heart, few cells (2-3%) are retained in the heart one month post-
transplantation [23]. We believe that by improving the survival and retention of 
transplanted CMCs we can cause a greater attenuation of ventricular dysfunction.  To 
improve survival and retention of transplanted CMCs, we sought to identify and establish 
human CMCs with enhanced proliferation and survival characteristics by 1) identifying 
telomerase reverse transcriptase (TERT)-expressing cells among CMCs and 2) targeting 
the expression of TERT to CMCs.  
TERT is the active subunit of telomerase holoenzyme that works in conjunction 
with an essential RNA subunit, known as TERC, and several species-specific proteins to 
maintain the ends of the DNA called the telomere [27]. Telomeres are DNA-protein 
structures found at both ends of each chromosome that protect the genome from nucleolytic 
degradation, unnecessary recombination, repair, and interchromosomal fusion [28]. 
Telomerase acts to prevent attrition of the telomeres to preserve the information in the 
genome as cells divide, permitting continued cell proliferation [29]. During mitosis, the 
 10 
DNA polymerase cannot fully replicate the 3’ end of the lagging strand of DNA creating 
an overhang [30].  If the telomerase holoenzyme is present, it finds this overhang and 
extends the 3’ end to maintain the telomere as illustrated in Figure 2. If telomerase is not 
present, the telomeres will progressively shorten at a rate of 50-100 base pairs of the 
terminal telomeric sequence (TTAGGG) with each population doubling [31] causing a 
limitation in the number of times the cell can divide, a phenomenon referred to as the 
Hayflick Limit [32]. Over time, the telomeres shorten and reach a critical length and induce 
either replicative senescence (Figure 2), apoptosis or continued proliferation accompanied 
by genomic instability [33]. 
Although telomerase expression has been detected in neonatal human somatic cells 
[34], most adult somatic cells do not express telomerase or maintain the telomere length 
during proliferation (Figure 3) [31]. The Hoffman group performed an extensive study in 
1998 looking at TERC expression, TERT mRNA expression and TERT activity throughout 
21 weeks of gestation of various human tissues, including the heart. In the heart, it was 
found that TERT activity could be detected until the 11th gestational week, but found that 
 
Figure 2 – Without telomerase activity, the end of the DNA, called the telomere, progressively 
shortens as the cell continues to divide. The telomere will reach a length called the Haflick limit 
that will result in the cells becoming senescent. However, telomere attrition is circumvented 
with the activity of telomerase allowing cells to continue to divide. 
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TERC was detected at all time points. These results suggest that telomerase is 
developmentally regulated and that TERT is the limiting subunit of telomerase activity in 
the heart, providing a rationale to focus our attention on TERT in the current study.  
However, it has also been observed that telomerase can be re-activated in quiescent 
cells such as contact inhibited fibroblasts using growth factors indicating the possibility of 
recrudescence of telomerase activity [35]. As previously mentioned, the terminally 
differentiated adult heart does not express TERT and lacks telomerase activity, but in the 
pathological heart cardiomyocyte hypertrophy and non-cardiomyocyte cell hyperplasia 
occurs, which may present the possibility of a re-activation of TERT. In a study performed 
by Richardson et al., a transgenic mouse was created in which the TERT promoter drove 
GFP expression in all cells [36]. Following cryoinjury, the authors detected an increased 
percentage of TERT expressing cells was detected in injured transgenic mouse hearts. In 
addition, the number of GFP expressing, TERT positive cells was also examined in non-
 
Figure 3 -  This figure demonstrates the association of telomere length with telomerase 
activity as cells continue to divide. The lines on the graph represent the progression of 
different types of cells in relation to their telomere length and telomerase activity. 
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injured 3- and 12-month-old mice. Counter to others findings that show no TERT 
expression in adult somatic cells, TERT could be detected in less than 0.03% of cardiac 
cells in the non-injured heart which may indicate that previous studies did not have enough 
sensitivity to detect the low level of TERT present in the heart. The researchers then 
attempted to characterize these cells and found that the TERT expressing were made up of 
a heterogenous mix of cells. It was further speculated that TERT-expressing cells represent 
a rare subpopulation of cardiomyocytic, endothelial and fibroblast lineage cells. Anversa’s 
group also found TERT expression in the injured hearts of dogs [37]. However, TERT 
expression was found to be isolated to cardiomyocytes. Taken together, these findings 
reveal that TERT may be present in the heart at very low levels making detection possible, 
but challenging. Results also indicate that TERT is expressed heterogeneously in the 
cardiac cells which could mean that TERT is also expressed in some CMCs. Data suggests 
that TERT may be reactivated in the injured heart, which may be critical to the survival 
and/or protection of cardiac cells.  
The protective characteristics of TERT are supported by evidence that TERT 
overexpression causes cardioprotection [38, 39]. Cardioprotection is defined as "all 
mechanisms and means that contribute to the preservation of the heart by reducing or even 
preventing myocardial damage" [40].  To test this, a transgenic mouse model was created 
to overexpress TERT in the heart [38]. It was found that transgenic overexpression of 
TERT resulted in a 50% reduction in apoptosis after myocardial infarction (MI) and an 
infarct reduction of 25% compared to transgenic mice with catalytically inactive TERT. 
However, the normal, non-infarcted hearts were concentrically hypertrophic in both 
ventricles suggesting that infarct reduction could be a result of hypertrophy of the heart. In 
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an attempt to circumvent hypertrophy observed by this group, Maria Blasco’s group 
overexpressed TERT in the whole mouse heart using a cardiospecific adeno-associated 
virus of serotype 9 (AAV9) [39]. Unlike the transgenic mouse model, an alteration of heart 
morphology was not observed in the normal heart. Consistent with the transgenic model, 
after MI, a reduction in scar size, a reduction in fibrosis and a significant improvement in 
ejection fraction was also observed in mouse hearts treated with AAV9 compared to 
untreated hearts. Although TERT overexpression preferentially targeted cardiomyocytes 
in the heart, neither study ruled out the potential effects of non-targeted TERT expression 
in other cardiac cell types so it is unclear what cardiac cells benefit from hTERT 
overexpression. The Blasco study does provide evidence that cardiac fibroblasts are not 
transduced, but failed to address other cell types present in the heart.  It is notable that the 
AAV9 also preferentially targets hepatocytes, but the efficiency is about ten-fold lower 
than cardiomyocytes. In both overexpression studies, there is uncertainty of whether TERT 
expression is protective or reparative. This indicates that it may be possible to prolong the 
survival and/or reparative characteristics of cells used in cell therapy by introducing TERT 
expression to them.  
To explore TERT overexpression of cultured cells, Armstrong et al. overexpressed 
TERT in embryonic stem (ES) cells and found that overexpressed ES cells were more 
resistant to stress [41], which is consistent with the protective characteristics of TERT 
overexpression previously discussed. While ES cells proliferate indefinitely, the ES cells 
with TERT overexpression also had an increase in the rate of population doubling. And 
TERT overexpression improved the proclivity of ES cells to differentiate into a 
hematopoietic lineage, indicating the possibility that TERT expression may help overcome 
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the differentiation deficiency observed in other studies transplanting CMCs [42]. 
Consistent with Armstrong’s findings in vitro, the Xu group overexpressed TERT in human 
nucleus pulposus cells (HNPC), a chondrocyte-like cell, and witnessed improved 
proliferation of the cells [43]. Moreover, it was found TERT-expressing HNPCs 
experienced less apoptosis and were protected from cell cycle arrest under serum 
starvation. It was speculated that that serum starvation-induced apoptosis and cell cycle G1 
arrest is regulated by the gene expression of p53, CCNE1, Fas, and Caspase 3 in the HNPCs 
overexpressing hTERT, which they found to be upregulated. In an in vivo study by 
Madonna et al., bone marrow mesenchymal stem cells were overexpressed with TERT and 
Myocardin and then transplanted into a ligated mouse hind limb [44]. After 15 days, there 
was a significant improvement in blood flow recovery in the ligated leg compared to PBS 
and Mock treated groups. It was also found that TERT overexpressing cells, without 
Myocardin overexpression, had an elevated paracrine activity as indicated by a significant 
increase in VEGF secretion into the cell supernatants. Paracrine stimulation by transplanted 
cells is speculated to be one of the causes of improvement in cardiac cell therapy [45], 
making this feature of TERT overexpression particularly interesting. It is also important to 
mention that bone marrow-derived mesenchymal cells do not endogenously express active 
TERT [46] which may be synonymous to cardiac-derived mesenchymal cells.  
In another in vivo study, Mark Sussman’s group transplanted cardiac progenitor 
cells overexpressing Pim-1 kinase into the infarcted heart [26]. The Pim-1 kinase 
overexpressed cells transplanted into the infarcted heart resulted in improved retention of 
transplanted cells and a greater improvement of ventricular function compared to GFP 
transduced progenitor cells [26]. It was also found that Pim-1 kinase overexpression 
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indirectly increased TERT expression in the cardiac progenitor cells. Although it is 
possible that ancillary TERT expression from Pim-1 kinase overexpression had little to do 
with the experimental results since several other protective mechanisms are also 
upregulated, the results follow the same trend as other TERT overexpression studies.  
Disregarding TERT overexpression in the Pim-1 kinase study, the findings do 
confirm that improvement of retention of transplanted cells leads to improvement of 
ventricular function in the infarcted heart. These results support our overall goal of the 
current study to prolong the survival of transplanted CMCs to ameliorate cardiac 
dysfunction. The combined results from these experiments suggest that overexpression of 
TERT may improve cardiac cell therapy through enhancing proliferation and survival of 
CMCs. Furthermore, overexpressing TERT in CMCs may lend to improved tissue repair 
via paracrine stimulation of the endogenous cardiac cells.  
It is also worth considering that there are secondary mechanisms of TERT, outside 
of telomere maintenance, that could be responsible for therapeutic potential of TERT. 
There are less-understood telomere-independent actions of TERT that make it an 
interesting target for cardiac cell therapy as well. For example, Zhou et al. observed a 
positive correlation between TERT expression and vascular endothelial growth factor 
(VEGF) promoter activity and expression in Hela cells, independent of telomerase activity 
[47]. To examine this, Hela cells were transiently transfected with TERT overexpression. 
A concomitant increased expression of VEGF was seen in TERT overexpressed Hela cells. 
To explore promoter activity, the group co-transfected Hela cells with TERT 
overexpression and a luciferase reporter driven by the VEGF promoter. A four-fold 
increase in the VEGF promoter activity was found when co-transfected with TERT 
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compared to the control vector. The finding is consistent with the results seen by Madonna 
et al. in the TERT and Myocardin overexpression study which observed an increased 
expression of VEGF, previously discussed [44]. In another study, TERT was revealed to 
promote U2OS cell invasion through an up-regulation of matrix metalloproteinase-9 
(MMP9), again independent of telomerase activity [48].  To perform this, U2OS cells were 
transfected with either a TERT overexpression vector or a catalytically inactive TERT 
vector. It was found that both the TERT and catalytically inactive TERT caused an increase 
in invasion through a Matrigel barrier and an upregulation of MMP9 compared to 
untransfected cells. Taken together, there is evidence that TERT is not only important in 
cell proliferation, but also plays a role in angiogenesis, cell differentiation and cell 
migration [49]. If TERT expression is effective in CMCs, the action of TERT could include 
a greater migration of transplanted CMCs into the damaged myocardium by upregulation 
of MMP9; an increase in paracrine stimulation and enhancement of blood flow to the 
ischemic zone through VEGF stimulated angiogenesis; an increased proclivity to 
differentiate similar to what was seen in ES cells; and improved survival and an increase 
in proliferation of the transplanted CMCs within the infarcted heart to prolong the 
therapeutic effects of cardiac cell therapy. It should be noted that all qualities of TERT 
expression discussed are also important for the progression of cancer. 85-90% of human 
tumors constitutively express TERT [50] (Figure 3), but many studies have shown that 
TERT itself is not tumorigenic [51-53].  
In our study, we sought to identify if TERT expression in CMCs has proliferative 
advantages and assessed if these cells present any ancillary benefits of TERT, such as 
protection and migration, in vitro. We hypothesized that TERT expression in CMCs 
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(endogenous or exogenous) would improve the survival and proliferation of human CMCs 
and prolong their therapeutic potential. We also believed that based on previous findings 
by other groups, TERT expression would result in enhanced migration of CMCs into the 
damaged myocardium, improved paracrine stimulation of endogenous cardiac cells 
resulting in angiogenesis, a reduction in damaged myocardial tissue and ultimately an 
improvement in ventricular function (Figure 4). While previous studies reveal TERT 
expression as valuable in other cells, TERT expression in CMCs has yet to be examined. 
As previously stated, it is commonly observed that TERT is not expressed or active in 
somatic, human cells [54], but was later shown to be expressed at very low levels in the 
normal heart and upregulated in the pathological heart [36, 37]. Until now, it had not been 
determined if CMCs being isolated for cell therapy endogenously express TERT. First, we 
attempted to identify and isolate human CMCs that endogenously express TERT. 
Additionally, we exogenously overexpressed TERT in CMCs, which had not been tested 
previously. After performing these experiments, our results show a lack of endogenous 
TERT expression and activity in CMCs. Unexpectedly, overexpression of active TERT in 
CMCs did not improve proliferation, survival or migration of CMCs in vitro, giving little 
 
Figure 4 - Intramyocardial transplantation of TERT-expressing CMCs into the border zone of 
the infarct. We hypothesized a greater infiltration and paracrine stimulation of TERT-
expressing CMCs in the infarcted heart. We believed this would improve angiogenesis, reduce 
the damaged, ischemic heart muscle and improve cardiac function. 
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evidence or justification that TERT expression alone in CMCs would improve cardiac cell 
therapy. 
 
Materials & Methods 
Explanting CMCs 
Human right atrial appendage was collected from patients during coronary artery 
bypass graft or valve replacement at Jewish Hospital by University of Louisville. A written 
consent was provided for the collection of the right atrial appendage following the protocol 
approved by the Institutional Review Board at the University of Louisville. To process the 
appendage tissue, all extraneous tissue was first removed (i.e. adipose tissue, etc) and then 
tissue was thoroughly cleaned using sterile 1X PBS. Then, tissue was finely minced with 
sterile surgical scissors and then minced tissue was digested.  
Collagenase digestion was prepared by adding 25 mg of collagenase crystals 
(Worthington Labs, Lot#421T3577, 320 Units/mg) to 20 mL of 1X PBS to achieve a final 
concentration of 2000 Units/mL. Solution was vortexed until crystals dissolved and then 
filtered by a 0.2 µm cellulose acetate syringe filter (VWR). Collagenase solution was added 
to the minced heart tissue, vortexed and incubated at 37 oC on an agitator for 30 minutes, 
vortexing every 10 minutes. Sample was removed from the incubator and the volume raised 
to 50 mL with 1X DMEM media containing 20% fetal bovine serum (FBS). It was 
centrifuged at 600 G for 10 minutes after which the supernatant was aspirated. The pelleted 
cells & tissue was resuspended in complete media (CM).  Digested tissue was incubated in 
the CM at 37 oC with 5% CO2, changing the media every 2 days and allowed to adhere to 
the plate. The outgrowth of adherent cells was harvested 7-10 days later. Human CMCs 
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complete media (CM) contained: Ham’s F12 (Gibco) containing 10% FBS (Seradigm), 10 
ng/mL bFGF (Peprotech), 0.005 U/mL human erythropoietin (Sigma) and 0.2 mM L-
Glutathione (Sigma) and 100 U/mL Penicillin-Streptomycin (ThermoFisher).  
It should be mentioned that an alternative method of digestion was also tested in 
which Collagenase was replaced with TrypLE (ThermoFisher). The digestion protocol was 
followed in the same manner as above. Additionally, some plates were coated in fibronectin 
(Sigma), while other plates were not coated. No difference was detected between methods 
the different techniques examined.  
 
Quantitative PCR Analysis 
mRNA was harvested from cells, treated with DNase (Qiagen) and purified using 
the RNeasy Kit (Qiagen) following the manufacturers protocol. cDNA was synthesized 
from 250 ng of mRNA using the AffinityScript qPCR cDNA Synthesis Kit (Agilient). 
qPCR analysis was then performed on samples in duplicate. The primer pairs used include:  
Human Primers 
Marker Primers 
TERT CCTCACCCACGCGAAAACCT, TGGGCCGGCATCTGAACAAA 
THY1 GCACTCCTCGGCAGGCATGG, TGGGCCAAACCCTGTGCAGC 
FSP1 TGGTTTGATCCTGACTGCTGTCATG, 
CTCCCGGGTCAGCAGCTCCT 
VE CAD ACAGCATCTTGCGGGGCGAC, CCCGCGGGAGGGCTCATGTA 






TNNT2 AGAAGGCCAAGGAGCTGTGGCA, CCAGCGCCCGGTGACTTTAGC 
MEF2C CAGGAATTTGGGAACTGAGCTGTGC, 
CGGCTCTCATGCGGCTCGTT 
GATA4 CGGCGAGGAGGAAGGAGCCA, TGGGGGCAGAAGACGGAGGG 
cKIT TGGGCCACCGTTTGGAAAGCT, 
AGGGTGTGGGGATGGATTTGCTCT 
DDR2 GGGCAGTGCTCCCTATCCGCT, CATGGCCAGGCACTGACAGCA 
NG2 GCGATGCCTTCTCGCTGGAT, CCGTCATGCACGTAGCGGAT 
CD146 CGTCTGTGCCCAGCATACCC, TGGTGTTTTTGCCCAGGTCGT 
PW1 CCCTTCCTGTGGTGGCGAAA, GATGAGTGGCCCTGCGTCAT 
CD31 TCCCAGGAGCACCTCCAGCC, TGGACCTCATCCACCGGGGC 
GFP ACCCTGACCTACGGCGTGCA, TAGCCTTCGGGCATGGCGGA 
β-ACTIN GCAGTCGGTTGGAGCGAGCA, 
ATCACCTCCCCTGTGTGGACTTGG 
Table 1: This table provides a detailed list of primers designed for humans and their specific bases.  
Results were analyzed for selected marker expression using SYBR Green Master 
Mix (Applied Biosystems) and 7900HT Fast Real Time PCR System with SDS version 
2.4.1 (Applied Biosystems). Dissociation curves were compared to controls for accuracy 
and CT values were compared among duplicates. If dissociation curves did not align with 
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the control, the results were deemed as undetected. If CT values were dramatically different 
between duplicates, the experiment was repeated for validation. 
 
hTERT Reporter 
An hTERT (human TERT) reporter construct was created using a 455 bp hTERT 
promoter, cut from a pGEM-hTERT construct [55], that drives EGFP and puromycin 
resistance (Figure 5). The construct was cloned and amplified using NEB Stable Competent 
High Efficiency E. coli (New England Biolabs) and was harvested using HiPure Plasmid 
Filter Midiprep Kit (Invitrogen). The reporter was validated by sequencing. Lipofectamine 
Plus (Invitrogen) transfection was performed in mouse myoblasts (C2C12 - known TERT 
positive) and Normal Human Dermal Fibroblasts (NHDFs – known TERT negative). Cells 
were co-transplanted with CMV-Histone H2B-mCherry. GFP & mCherry fluorescence 
was confirmed with epifluorescence microscopy using an EVOS FL microscope.  
 
hTERT Overexpression Vector 
The 3.4 kb hTERT transcript was cloned into a pLVX-Puro lentiviral vector 
followed by a GFP reporter (Figure 6). The hTERT, Puromycin resistance and GFP 
 
Figure 5 - The hTERT reporter construct consisted of a 455bp hTERT promoter driving 
EGFP expression in hTERT positive cells. It was followed by a constitutively active SV40 
promoter driving Puromycin Resistance expression to protect successfully transduced cells. 
Successful transduction would yield puromycin resistant cells that were both GFP+ and GFP-. 
If TERT was expressed in the transduced cells, GFP was translated.  
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reporter transcripts were separated by a self-cleaving peptide (i.e. E2A, T2A), as seen in  . 
Additionally, an empty vector that lacks hTERT was produced as a control. Again, the 
constructs were cloned and amplified using NEB Stable Competent High Efficiency E. coli 
(New England Biolabs) and was harvested using HiPure Plasmid Filter Midiprep Kit 
(Invitrogen). The vectors were validated by sequencing the construct. Lipofectamine Plus 
(Invitrogen) transfection was performed on C2C12 cells and GFP expression was 
visualized with epifluorescence. The presence of hTERT was then verified in these 
transfected cells by Immunocytochemistry and Western Blot using an anti-TERT antibody 
(Rockland, 600-401-252S) [15]. 
 
Immunocytochemistry 
Cells were plated on a coverslip in the well of a 6-well plate and allowed to incubate 
overnight at 37 o C in CM. The next day, cells were washed in 1X PBS and then fixed using 
3.7% Formaldehyde for 15 minutes at room temperature (RT). Cells were then washed 
twice with 1X PBS and permeabilized with 0.25% Triton X-100 for 10 minutes at RT. 
After being permeabilized, cells were washed twice with 1X PBS and then blocked with 
 
 
Figure 6 – Top: A constitutively active CMV promoter is driving 2 Myc tags followed by 
hTERT overexpression transcript. It is followed by Puromycin resistance and GFP expression 
that is separated by self-cleaving peptides to provide a 1:1:1 expression. Bottom: The empty 
vector is similar to the hTERT overexpression vector, but it lacks hTERT. 
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5% Bovine Serum Albumin (BSA) for 30 minutes at RT. We then diluted the primary 
antibody, Rabbit anti-TERT (Rockland, 600-401-252S), in a 1:150 dilution with 5% BSA 
and incubated the cells in the primary antibody solution. Next, the solution was decanted 
and the cells washed with 1X PBS three times, letting the last wash incubate for 15 minutes. 
During that time, we diluted the secondary antibody, Alexa Fluor 555 Goat Anti-Rabbit 
IgG (Invitrogen), by 1:1000 and incubated the cells in the secondary antibody solution in 
the dark for 1 hour. The cells were again washed with 1X PBS three times and then 
counterstained with 1X DAPI staining solution for 1 minute in the dark, followed by being 
washed with 1X PBS three times. All excess 1X PBS was removed from the slips. A drop 
of mounting medium was added to a glass slide and the coverslip carefully placed on the 
slide. After the medium dried, the edges were sealed with clear nail polish. Results were 
observed with epifluorescence microscopy. 
 
Lentivirus Production, Transduction and Puromycin Selection 
Lentivirus was produced using the ViraPower Lentiviral Expression System 
(Invitrogen) per the manufacturer’s protocol. Briefly, on the first day of virus production, 
293T Cells (Clontech) in a 100 mm dish were cultured in 8 mL of Opti-MEM (Gibco) 
containing 3 µg of DNA, 9 µg of Packaging Mix (Invitrogen) and 360 µL of 
Lipofectamine 2000 (Invitrogen) and then incubated overnight. The next day, the media 
was changed to antibiotic-free media and incubated another day. On the 3rd day, we 
checked the virus titer with Lenti-X Go Stix (Clontech). Once the titer gave a positive 
result, the virus was harvested and then concentrated using Lenti-X Concentrator 
(Clontech) overnight. Concentrated virus was then diluted 10X and stored in aliquots at   
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-80 oC for later use. On the day of transduction, the virus was thawed and human CMCs 
were transduced with the vector of interest (previously described) and 6 µg/mL of 
polybrene (Sigma). 
The next day, the transduction media was replaced with fresh CM. After 2-5 days, 
transduction was verified using epifluorescence microscopy to identify GFP expressing 
cells. CMCs were then treated with 1.5 µg/mL of Puromycin (Thermofisher) in CM to 
select for the puromycin resistant cells. The optimal Puromycin treatment concentration 
was determined prior to beginning this experiment. After selection, GFP was again verified 
by epifluorescence microscopy. Selected CMCs were then maintained in 0.5 µg/mL of 
Puromycin supplemented CM to prevent growth of cells not expressing Puromycin 
resistance. 
 
Flow Cytometry & MoFlo Cell Sorting 
 To check the percentage of GFP expression in transduced CMCs and NHDFs, flow 
cytometry was used to count the number of GFP positive cells relative to GFP negative 
cells using the BD LSR II and FACSdiva software. Briefly, data was acquired from 
untransduced cells. P1, P2 and P3 gating was established in the FACSdiva software which 
identified the cells expressing GFP. Once gating was set, we ran the experiment on the 
transduced cells. This data determined the percentage of GFP positive cells within the 
transduced cells.  
 Additionally, we collaborated with Dr. James McCracken to perform MoFlo 
(modular flow) cell sorting using a MoFlo XDP system (Beckman Coulter). The MoFLo 
system is a high-speed cell sorting system that precisely sorts rare cell populations. Using 
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this system, we sorted out the top 5% and bottom 5% of GFP expressing cells within the 
transduced population. We captured these cells in 1.5 mL Eppendorf tubes and 
immediately harvested the RNA using the RNeasy Mini Kit (Qiagen) to perform qPCR 
(previously described). 
 
Western Blot Analysis 
Protein was harvested from CMCs using a Laemmli buffer and then heated at       
100 oC for 10 minutes. A bicinchoninic acid assay (BCA) kit (Thermo Scientific) was used 
to measure the protein concentration of each sample, per the manufacturer’s protocol. Once 
measured, 3 µL of β-mercaptoethanol per 100 µL of sample was added to an Eppendorf 
tube and then heated at 100 o C for 3 minutes. Using the concentration acquired from the 
assay, 50 µg of protein was loaded on the NuSep precast gel (VWR) alongside a PageRuler 
Plus Prestained Protein Ladder (ThermoFisher). The gel underwent electrophoresis at     
100 V until the ladder was 1 cm from the bottom of the gel. The separated proteins were 
transferred to a polyvinylidene difluoride (PVDF) membrane (Millipore) and the transfer 
was confirmed with Ponceau (Mallinckrodt Chemicals) staining. The membrane was then 
blocked with 5% skim milk for 1 hour. Proteins were probed with a primary antibody 
(1:1000 dilution) overnight at 4 o C. The next day, the primary antibody solution was 
decanted, the membrane was washed with Tris-Buffered Saline Tween 20 and then 
incubated with HRP-conjugated secondary antibody (1:10000 dilution) for 1 hour. The 
results were developed using an Amersham ECL Prime Western Blot Detection Reagent 
(GE Healthcare) purchased through VWR and visualized with MyECL Imager 
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(ThermoFisher). The primary antibody anti-hTERT (Rockland, 600-401-252S) was used 
to detect TERT and the secondary Anti-body was Goat Anti-Rabbit HRP (Pierce). 
 
Telomeric Repeat Amplification Protocol (TRAP) 
To measure telomerase activity, a TeloTAGGG Telomerase PCR ELISA Kit 
(Roche) was utilized based on the manufacturers protocol. Briefly, the TeloTAGGG kit 
uses PCR and biotin-labelled primers to amplify the product produced by telomerase. The 
amplified product is then immobilizeded to a 96-well ELISA plate and hybridized with a 
digoxigenin (DIG)-labeled, telomeric repeat-specific detection probe.  An anti-DIG 
antibody conjugated to peroxidase produces a colored reaction and is used to translate the 
quantity of product into absorbance. The more telomerase activity present resulted in a 
higher absorbance. The results of the kit were displayed as absorbance at 450nm and 
compared to an RNase treated isolate as a negative control. Human CMCs transduced with 
hTERT were compared to cells transduced with an empty vector in the same cell line. This 
was performed in triplicate and compared to NHDFs, a known hTERT negative cell line, 
and HeLa Cells, a known hTERT positive cell line. The kit also included a positive control 
cell extract as a reference. 
 
Population Doubling Time 
Population doubling time, in the simplest terms, is the time is takes for a population 
of cells to double in the number of cells. In this study, population doubling of hTERT 
overexpressed CMCs were compared to CMCs transduced with an empty vector. Cells 
were grown to 90% confluence and then passaged (as previously described). CMCs were 
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resuspended in CM and counted using a hemocytometer (Bright-Line). 1.5x106 CMCs 
were plated on 100 mm dishes after each passage. Passaging was repeated until CMCs 
appeared senescent. To calculate doubling time, the number of CMCs counted was divided 
by the number of cells plated to arrive at value A. Then the number of days between 
passaging was divided by A to enumerate the number of days it takes the double the 
population of CMCs. Population doubling level (PDL) was calculated by the equation 
PDL=X+3.322(log Y - log I) where X is the current doubling level, Y is the yield of cells 
produced and I is the initial number of cells plated. Doubling was performed in biological 
replicates. The mean doubling rate was observed to identify if hTERT overexpression 
resulted in an increase in proliferation rate while population doubling level was used to 
identify if hTERT overexpression immortalized the CMCs. 
 
Oxidative Stress Induced by DMNQ 
To test hTERT overexpressed CMCs resistance to oxidative stress, 1x104 hTERT 
overexpressed CMCs and control CMCs were plated in triplicate on a 96-well cell culture 
plate. Varied concentrations of DMNQ (dimethoxy-naphthoquinone; Sigma) was added to 
CM to final concentrations of: 0.0 µM, 0.25 µM, 0.5 µM, 0.75 µM, 1 µM, 1.25 µM, and 
1.5 µM. The next day, a colorimetric cell viability reagent called PrestoBlue (Invitrogen) 
was used following the manufacture’s protocol. Viability of the CMCs was measured by 
absorption at Ex/Em 560/590 nm on a Biotek Synergy system. The absorption results were 
graphed as a percentage of the absorbance of the 0.0 µM DMNQ treated wells to determine 
the fraction of remaining viable cells.  
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Of note, H2O2 was also tested as a method of inducing oxidative stress. However, 
colorimetric results were inconsistent between experiments making H2O2 induced 
oxidative stress in CMCs less reliable. While the experiments were performed, the results 
from oxidative stress induced by H2O2 treatment were not used in this study. 
 
Cell Migration Assay 
To test migration, 1x104 hTERT expressing CMCs and control CMCs were plated 
on Boyden chambers containing transwell membranes with a 8 µm pore size (Corning). 
After 24 hours, the media in the upper chamber was replaced with non-supplemented, 
serum-free Ham’s F12 media (Gibco) and the bottom chamber was replaced with Ham’s 
F12 media (Gibco) containing only 2% FBS (Seradigm). 24 hours later, cells that migrated 
to lower surface of the transwell membrane were fixed with 3.7% formaldehyde for 10 
minutes. Cells remaining in the upper chamber were removed using a cotton tip. Fixed cells 
were washed in 1X PBS for 10 minutes and then incubated with 50 µg/mL of propidium 
iodide solution for 10-15 min. Migrated CMCs were quantified by counting the number of 
cells within four different fields taken with the EVOS FL Cell Imaging System (Life 
Technologies).   
 
Results 
Endogenous hTERT Detection 
 To begin, we explanted CMCs from human right atrial appendage, as described in 
the methods. Briefly, atrial appendage tissue was digested with collagenase and then plated 
on a 100 mm plate. The media was changed every 2 days and digested tissue was incubated 
at 37 oC with 5% CO2 for 7-11 days. The adherent CMC outgrowth was harvested and 
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expanded in CM. CMCs were transferred to a 6-well plate and the next day 
immunocytochemistry was performed to detect endogenous hTERT using an Anti-TERT 
primary antibody from Rockland. The antibody was selected because previous studies 
showed successful detection of hTERT both in immunocytochemistry and Western blot 
[56]. In our hands, the anti-hTERT antibody produced an indistinguishably low-level of 
fluorescence among Hela, NHDFs and CMCs (Figure 7). Since Hela cells (positive control) 
had undetectable results, the low level of fluorescence among all cells was interpreted as 
inconclusive. Later, we overexpressed hTERT in C2C12 cells and again used the Rockland 
antibody to perform immunocytochemistry. In this experiment, the Rockland anti-hTERT 
antibody convincingly detected hTERT in C2C12 cells overexpressing hTERT, leading us 
to conclude that the antibody was not able to detect endogenous hTERT in Hela, NHDFs 
and CMCs (Figure 7).  
 Next, we harvested mRNA using the RNeasy Kit (Qiagen) following the 
manufacturers protocol. cDNA was synthesized from 250 ng of mRNA using the 
AffinityScript qPCR cDNA Synthesis Kit (Agilient). We then ran quantitative RT-PCR 
using the primers previously described to detect hTERT and other cardiac cell markers. 
For a positive control for hTERT, we used mRNA harvested from the thymus (Clontech) 
because the thymus had been previously observed to express hTERT [57]. While we 
detected hTERT expression in the thymus, we were unable to detect hTERT in CMCs 
(Figure 8A) from nine different patients. hTERT was also undetected in a whole heart 
sample, purchased from Clontech.  
Despite the lack of hTERT detected in human CMCs from 9 patients, we were able 
to do a preliminary characterization of the CMC populations using a selection of other 
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cardiac cell markers (Figure 8, Figure 9). From those results, we concluded that within the 
human CMCs we have no myocyte marker expression (Figure 9B) and very little 




Figure 7 - Immunocytochemistry was performed on Hela, NHDFs and CMCs. Hela is known 
to be hTERT positive while NHDF is known to be hTERT negative, acting as controls to 
compare CMC hTERT detection. On the left is the epifluorescent images of the anti-hTERT 
antibody and on the right is a phase contrast image of the same field to provide a reference of 
the cells present. Detection of hTERT with the antibody among all cell types appeared 









endothelial cell marker expression (Figure 8C, Figure 9A) suggesting that these cell 
populations do not contain cardiomyocytes and very few endothelial cells. Likewise, 




Figure 8 - Using quantitative RT-PCR, we tested expression of a variety of cardiac markers 
(previously outlined) among 9 different patients. All samples were normalized to β-Actin, a 
ubiquitously expressed transcript. A. hTERT expression was compared to the thymus, a 
known hTERT positive tissue in humans. Other cardiac markers were compared to whole 
heart (Clontech) expression. B. Fibroblast Markers, THY1 & FSP1, were expressed at varying 
levels. C. Endothelial Markers, CD31 & VE CAD, were expressed at low levels relative to the 





However, we did observe variable fibroblast (Figure 8B) and smooth muscle cell marker 





Figure 9 - Using quantitative RT-PCR, we tested expression of a variety of cardiac markers 
(previously outlined) among 9 different patients. All samples were normalized to β-Actin, a 
ubiquitously expressed transcript. A. Endothelial Marker, KDR, was expressed at low levels 
relative to the whole heart, similar to CD31 & VE CAD. B. Myocyte Marker, Tnnt2, was 
undetectable. C. Smooth Muscle Markers, aSMA & SM22a, had variable levels of expression. 
D. Development Markers, MEF2C, GATA4 & c-Kit, are all expressed at relatively low levels 






highly than in the whole heart sample. While at this point there are no surface markers that 
have been exclusively associated with mesenchymal cells, the initial expression results 
from human CMCs in the current study are consistent with a mesenchymal cell profile 
further confirming the identity of the CMC population harvested in this study [58]. 
  To exhaust our search for endogenous hTERT in CMCs, we created an hTERT 
reporter vector (Figure 5). Briefly, in the construct a 455 bp hTERT promoter was driving 
GFP expression to label any CMC that expressed hTERT. Also included, the construct had 
Puromycin resistance being driven by a constitutively active CMV promoter. Only CMCs 
expressing TERT within the Puromycin selected population would express GFP, allowing 
us to test transduction efficiency as well as isolate a rare TERT-expressing population. 
After sequencing the hTERT reporter, we performed a co-transfection of C2C12 and 
NHDF with the hTERT-reporter and a constitutively promoted mCherry construct. From 
this, we expected to observe cells that were either mCherry+/GFP- (TERT negative), or 
mCherry+/GFP+ (TERT positive). We observed that NHDFs had mCherry+/GFP-, 
 
Figure 10 – NHDFs & C2C12 cells were co-transfected with the hTERT reporter and CMV-
Histone H2B-mCherry. A. The NHDF cells are mCherry+/GFP- indicating a successful 
transfection of TERT- cells. B. C2C12 cells were both mCherry+/GFP+ and mCherry+/GFP-, 
again indicating a successful transfection, but showing both TERT+ and TERT- cells within 
the C2C12 population. 
A. B. 
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indicating successful transfection with no TERT expression (Figure 10A). On the other 
hand, C2C12 cells had a mix of mCherry+/GFP+, mCherry+/GFP- cells, indicating a 
successful transfection and that TERT expression was present in only some of the C2C12 
cells (Figure 10B).  
 After successful hTERT reporter transfection, we produced the lentivirus 
containing the reporter. We tittered the virus and CMCs were successfully transduced. 
After 4 days, we used epifluorescence microscopy to observe GFP expression in the CMCs 
(Figure 11A) and NHDFs cells (not shown). Again, only cells that express hTERT should 
be GFP+, therefor we anticipated the NHDFs would have no detectable GFP and CMCs 
would have rare GFP expression. Upon visual inspection, a surprising number of CMCs 
and NHDFs expressed GFP. For this reason, we performed flow cytometry on the hTERT 
reporter transduced CMCs and NHDFs to determine the number of GFP-positive cells. It 
was found that in some cases, nearly 80% of the hTERT reporter transduced CMCs 
expressed GFP (Figure 11B). Counter to the hTERT reporter transfection results, nearly 
40% of NHDFs were GFP+. We concluded that our hTERT reporter failed to detect hTERT 
expression or there was no hTERT expression in the CMCs and NHDFs. It is possible that 
GFP expression was being driven by some non-specific promoter activity. To test if there 
was a failure to detect or lack of hTERT expression, we arbitrarily sorted out the top 5% 
and bottom 5% of GFP+ CMCs and NHDFs using MoFlo. It is possible that some of the 
GFP+ cells may indeed be hTERT positive, but was hidden by a discrepancy with the 
reporter virus. After successfully sorting the top and bottom 5% of GFP+ cells, we 
immediately harvested the mRNA from each aliquot of cells and synthesized cDNA to 
perform quantitative RT-PCR.  
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In the GFP sorted CMCs and NHDFs, we confirm GFP gene expression using 
quantitative RT-PCR in CMCs and NHDFs in both the top 5% and bottom 5% of GFP 
expressers (Figure 12A, B, C). However, we did not detect hTERT in any of the cells 
(Figure 12D). The lack of detection of hTERT gene expression in CMCs and NHDFs was 




Figure 11 – A. Human CMCs were transduced with the hTERT reporter. GFP+ cells were 
investigated with epifluorescence microscopy. Only cells that activate the hTERT promoter 
should be GFP+, but the number of cells expressing GFP is far higher than expected. B. Flow 
cytometry was performed to determine the percentage of transduced CMCs and NHDFs that 
express GFP. This was performed in Untransduced cells, NHDFs and in 2 separate patients, at 




reporter was not detecting hTERT, at any level, in the CMCs. We concluded that the GFP 
in our hTERT reporter was being non-specifically activated and was not sufficient to detect 





 Up to this point, endogenous hTERT was undetectable in CMCs. However, a 
secondary aim of this study was to exogenously overexpress hTERT in CMCs, thereby 
 
 
Figure 12 – hTERT reporter transduced CMCs (A.) and NHDFs (B.) were arbitrarily sorted 
for the Top 5% of GFP expressing cells (R3) and the bottom 5% of GFP expressing cells 
(R4). RNA from the sorted cells was immediately harvested and processed. C. Quantitative 
RT-PCR was performed, confirming GFP expression in the Top 5% (H) and bottom 5% (L) in 
two different patients (793 & 802) and NHDF (DFH) cells compared to untransduced NHDFs, 





overcoming a lack of endogenous hTERT. We again utilized a lentiviral delivery system, 
producing a constitutively active construct that expressed hTERT, Puromycin resistance 
and GFP, separated by self-cleaving peptides (Figure 6). We also created a transduction 
control vector that lacked hTERT (Figure 6). After confirming the sequencing, we again 
used Lipofectamine to transfect C2C12 cells to examine the efficacy of the vectors. For 
this experiment, we not only looked at GFP expression driven by hTERT overexpression, 
but we also performed immunocytochemistry using the anti-hTERT antibody (Rockland) 
to detect the presence of hTERT. We confirm that C2C12 cells transfected with the hTERT 
overexpression vector are GFP+ and the presence of hTERT can be detected using 
immunocytochemistry (Figure 13). Then, protein was harvested from hTERT transfected 
C2C12 cells to perform Western Blot. We confirmed that transient overexpression of 
hTERT in C2C12 cells did indeed translate detectable levels of hTERT compared to the 
control vector (Figure 14). Based on the results, transfection of C2C12 cells with the 
hTERT overexpression vector corresponds with GFP expression, detection of hTERT 
using immunocytochemistry (Figure 13) and the presence of translated hTERT using 
Western Blot (Figure 14). Whereas the control vector had GFP expression, but lacked 
hTERT detection with immunocytochemistry and Western blot.  
Therefore, we moved forward with lentivirus production of the hTERT 
overexpression vector and control vector. Lentiviruses containing the vectors were 
produced using the ViraPower Lentiviral Expression System (Invitrogen) so that 
overexpression could be integrated into CMCs. Then, human CMCs were transduced with 





Figure 13 – This figure demonstrates overexpression of hTERT in C2C12 cells using a 
Lipofectamine transfection. The left column is the DAPI stain of the cells in the field. The 
middle column is GFP expression detected in the transfected cells. In the right column, an 
Anti-hTERT antibody (Rockland) was used to detect hTERT expression using 
Immunocytochemistry. The first row of cells are untransfected C2C12 cells, which are GFP-
/hTERT-. The second row is an hTERT overexpression vector lacking GFP expression 
transfected cells, which is confirmed by GFP-/TERT+. The third row of cells are empty vector 
transfected cells which have GFP expression and lacks hTERT, confirmed by GFP+/hTERT-. 



























Transduced CMCs were then treated with 1.5 µg/mL of Puromycin to eliminate 
CMCs not expressing Puromycin resistance (Figure 15). After selection, surviving CMCs 
were maintained in 0.5 µg/mL of Puromycin. Results show that Puromycin resistant CMCs 
were also GFP-positive, thus far confirming the construct is working as designed (Figure 
15). For the final test to examine if our construct is working, we then verified hTERT 
overexpression in CMCs by harvesting mRNA from the transduced, selected CMCs. 
cDNA was synthesized and quantitative RT-PCR was performed. hTERT overexpressed 
CMCs had a 50-300-fold increase in hTERT expression compared to control treated CMCs 
(Figure 16A). We also harvested protein from transduced CMCs to perform Western Blot. 
We observed a significant band at 126.9 kDa in hTERT overexpressed CMCs compared to 
 
Figure 14 – Protein was harvested from C2C12 cells transfected with either hTERT 
Overpression (3X-FLAG-hTERT, pLVX-hTERT) or with the control vector (pLVX-Vector), 
compared to untransfected C2C12 cells. hTERT Overexpression could be identified by the 
presence of a band 126.9 kDa in size. 
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the control (Figure 16B), which had no detection of hTERT. From this, we concluded that 
the pLVX-hTERT vector was successful at expressing and translating hTERT in CMCs. 
Additionally, the transduced CMCs could successfully be selected and verified by GFP 
expression (Figure 15). We also further support our findings that hTERT is not 
endogenously present in CMCs in two additional patients by qPCR, as well as Western 
Blot (Figure 16). 
After revealing that the hTERT overexpression was successful at expressing and translating 
hTERT in CMCs, we then wanted to verify hTERT activity in the CMCs. To do this, we 
performed a TeloTAGGG Telomerase PCR ELISA assay (Roche). Briefly, this assay uses 




Figure 15 – Human CMCs were transduced with either pLVX-Vector control or pLVX-
hTERT overexpression vectors. 4-days after transduction, epifluorescence was performed to 
visualize the GFP expression (Top). Transduced CMCs were then treated with 1.5 µg/mL of 
Puromycin to select for the Puromycin resistant cells. Cells were maintained for 3-weeks in 




with biotinylated synthetic primers. If telomerase is present in the sample, it will add 
repetitive sequences to the 3′-end of the labelled primer. Then, the telomerase elongated 
products are amplified by PCR. The product is then hybridized with a detection probe and 
immobilized by the biotin-label. The immobilized PCR product is detected with an anti-
digoxigenin antibody conjugated to peroxidase, which metabolizes TMB to form a colored 
reaction measured as absorbance. Therefore, the more absorbance measured equates to 
more telomerase activity. We observed significantly more absorbance in CMCs 
overexpressing hTERT than in the empty vector transduced CMCs (Figure 17). In fact, the 
empty vector transduced cells had virtually no detectable level of activity, consistent with 
the lack of endogenous hTERT (Figure 16). Results from these experiments confirm that 
we successfully overexpressed an active form of hTERT in human CMCs. 
 
 
Figure 16 – A. mRNA was harvested from hTERT overexpressed and control transduced 
CMCs. cDNA was synthesized and quantitative RT-PCR was performed in two separate 
patients compared to the whole heart and thymus (Clonetech). The hTERT overexpressed 
CMCs show a 50-300-fold increase in hTERT expression. B. Protein was harvested from the 
transduced CMCs in two patients. hTERT was detected in hTERT overexpressed CMCs, 




hTERT Activity in CMCs  
Once active hTERT overexpression was confirmed in pLVX-hTERT tranduced 
CMCs, we then studied the characteristics of the TERT overexpressed CMCs. First and 
foremost, we maintained transduced CMCs (both hTERT and control) for a duration of 
over 50 days to test their proliferative capacity. Based on previous studies, hTERT   
overexpression immortalizes cells and allows for continued proliferation [59]. 
However, after growing the transduced CMCs for over 50 days, the CMCs were in poor 
health and appeared mostly senescent. We repeated with transduced CMC aliquots frozen 
at earlier passages and the same result occurred, only this time at a faster rate. With the 
concern of virus toxicity and/or contamination, we produced a new lentivirus and repeated 
the experiment at different viral dilutions with freshly created virus only to find the same 
 
 
Figure 17 - TeloTAGGG Telomerase PCR ELISA was performed on hTERT overexpressed 
CMCs compared to the empty vector transduced CMCs. Transduced CMCs were compared to 
Hela (known hTERT-positive), NHDF (known hTERT-negative) and a positive control 
included with the assay. One lane of each cell type was also treated with RNase to inhibit the 
telomerase activity as an additional control. 
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outcome. During the time that we tracked the traduced CMCs in culture, we found no 
change in the rate of doubling between the hTERT overexpressed CMCs compared to 
control vector transduced CMCs (Figure 18A). We also found that overexpressing hTERT 
in CMCs did not prolong the proliferation of CMCs compared to the control. In fact, the 
population doubling level in the hTERT transduced CMCs begin to plateau prior to the 
empty vector transduced cells (Figure 18B). Although active hTERT can be overexpressed 
in CMCs, hTERT alone does not improve the proliferative capacity of CMCs in culture. 
The phenomenon of immortalization caused by hTERT overexpression does not occur in 
CMCs in our hands.  
Despite the mortality observed in hTERT overexpressed CMCs, we continued to 
test some of the secondary characteristics of hTERT in CMCs. It is possible that the 
functionality of hTERT in CMCs differs from what has been reported in other cell lines. 
For this set of experiments, we subjected hTERT overexpressing CMCs to oxidative stress 
induced by DMNQ. Prior to beginning, we tested a range of DMNQ concentrations to find 
 
Figure 18 – A. Proliferation rate of the hTERT overexpressed CMCs was compared to vector 
transduced CMCs in two different patients in triplicate. No significant difference was detected 
in the growth rate. B. Population Doubling Level of the hTERT overexpressed CMCs (red) 
and compared to the control CMCs (black). The results displayed are Patient 1 CMCs. Patient 
2 CMC population doubling level followed a similar trend (not shown). 
A. B. 
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the LC50 of CMCs when treated with DMNQ. Then, transduced CMCs were plated in 
triplicate and treated with varying concentrations of DMNQ, up to the LC50 concentration. 
CMCs were incubated in DMNQ for 24 hours and then cell viability was measured using 
PrestoBlue, per the manufacturer’s protocol. We observed that hTERT CMCs were no 
more resistant to oxidative stress than vector transduced CMCs after treating with DMNQ 
for 24 hours (Figure 19A). Again, this differed from the results observed in other cell types.  





Figure 19 – A. CMCs transduced with either hTERT overexpression or a control vector were 
plated in triplicate and treated with DMNQ at the following concentrations: 0.0 µM, 0.25 µM, 
0.50 µM, 0.75 µM, 1.0 µM, 1.25 µM and 1.5 µM. After 24 hours, cell viability was measured 
using PrestoBlue. B. Migration was also tested by plating transduced CMCs in duplicate on 
transwell plates and allowing to migrate toward FBS overnight. No difference was found in 





To do this, we performed a Boyden chamber assay. Briefly, transduced CMCs were plated 
on the semi-permeable membrane of a transwell plate. The CMCs were incubated in CM 
overnight. The next day, the media in the top well of the transwell plate was changed to 
serum-free, basal media. The media in the bottom well was changed to Ham’s F12 
containing 2% FBS. Cells were incubated overnight. Prior to beginning this study, we 
examined different durations of migration to identify an optimal migration time for CMCs. 
It was found that overnight migration (18 hours) provided the most robust results. We 
found that migration of CMCs toward a chemoattractant (2% FBS) was not improved by 
the overexpression of hTERT (Figure 19B). Results of some of hTERT’s secondary 
characteristics suggest that hTERT expression in CMCs does not improve resistance to 
stress or improve migration, in vitro (Figure 19). Taken together, our observations indicate 
that overexpression of hTERT in CMCs has no observed therapeutic advantages in vitro. 
 
Discussion 
In this study, we comprehensively determined that CMCs lack endogenous 
expression of hTERT. Furthermore, we elucidated that the lifespan of explanted CMCs is 
not singularly reliant on the expression of hTERT. While we did look at the presence of 
hTERT and identify that hTERT was active in the CMCs overexpressing hTERT, we did 
not confirm that hTERT activity resulted in telomere maintenance. To perform this, a 
Southern Blot would need to be performed and probed to detect the segments of the 
telomeres compared to normal CMCs. If it was found that overexpression of hTERT does 
not maintain telomere length, it is possible that other factors are inhibiting the activity of 
the hTERT, allowing for telomere attrition. One possible example is the presence and 
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activity of the Shelterin complex [60]. If the Shelterin complex, or one of its six subunits, 
were not present and/or working as it should then maintenance of the telomeres could not 
be regulated by hTERT. POT1, one of the Shelterin subunits, has single-stranded-DNA 
binding activity that has been shown to be able to block telomerase from gaining access to 
the telomere [61]. In fact, introducing a mutant form of POT1 causes a loss of telomerase 
regulation and allows for telomeres to be overextended [62]. It is possible that POT1 could 
be highly active in CMCs, preventing hTERT access to the telomere. Of course, this is 
speculative and just one potential inhibitor of hTERT activity. 
It is also possible that the CMCs represent a population of cells that do not depend 
on hTERT for the maintenance of telomeres. Approximately 30% of in vitro immortalized 
human cell lines do not express hTERT [63]. CMCs may rely on an Alternative 
Lengthening of Telomere (ALT) pathway to prevent telomere attrition [64]. Despite the 
reliance on ALT for telomere maintenance, the Wen group found that in some cases that 
ALT and hTERT can co-exist in cells to maintain the telomeres.  In other words, 
overexpression of hTERT in cells relying on ALT can enhance telomere maintenance. 
However, they did identify that TERC must be present as well as hTERT. Although we 
overexpressed hTERT, we did not also verify the presence of TERC which could be an 
inhibitor of the hTERT activity. In any case, it would be challenging to identify the precise 
cause for the lack of telomere lengthening in cells overexpressing hTERT and is a project 
that is outside of the scope of the current study. 
 Additionally, it is possible that the telomere length is independent of proliferation 
of CMCs explanted from atrial appendage tissue. Several studies have reported that 
mammary epithelial cells and keratinocytes cannot be immortalized by hTERT 
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overexpression [65, 66]. In these studies, an inactivation of p16 along with hTERT 
overexpression was necessary to immortalize the cells, which presents the question of 
whether telomere length is the sole factor of senescence. Another group introduced ras into 
rodent cells and induced senescence, despite having sufficiently long telomeres [67]. 
Regardless, the hypothesis of this project was that expression of hTERT in CMCs would 
prolong the proliferation and longevity of these cells thereby improving cell therapy. 
Unfortunately, that was not found to be the case in our hands. Pinpointing the specific 
reason hTERT does not have the expected hTERT overexpression phenotype and the 
solution to that problem is beyond the scope of this project. This project simply sought to 
identify if hTERT alone could improve CMCs therapeutic potential, which we believe we 
have sufficiently addressed.  
 Even though CMCs overexpressing hTERT did not exhibit therapeutic potential, it 
is worth considering that CMCs are not the optimal cardiac cell population to achieve the 
benefits of hTERT overexpression. In a study performed by Leri et al. hTERT expression 
was detected exclusively in cardiomyocytes in the injured heart [37]. On the other hand, 
Richards et al. found hTERT expression was present in a heterogenous mix of cells in the 
non-injured heart [36]. This could indicate that the optimal target of hTERT overexpression 
in the heart has yet to be examined. Although CMCs weren’t fruitful for this project, it 
would be interesting to shift the approach to identify the cell lines in the heart that do 
express hTERT that could be used for cardiac cell therapy. For instance, it is possible that 
hTERT expression is indeed important in the cardiomyocytes similar to what was seen in 
the Leri et al. study. To test hTERT’s importance in cardiomyocytes, Zhang et al. reversibly 
overexpressed hTERT in cardiomyocytes so that cardiomyocytes could be expanded and 
 48 
then “turned off” using Cre recombinase [68]. Unlike CMCs, they observed that 
cardiomyocytes could be controllably immortalized with hTERT expression. It will be 
interesting to see the results of future experiments utilizing these cells in vivo for cardiac 
cell therapy. It would be of added interest to determine if hTERT expression in endogenous 
cardiomyocytes is enhanced after treatment with CMCs and if so, would blocking the 
stimulation of hTERT in cardiomyocytes eliminate the ventricular functional improvement 
observed. This again is beyond the scope of the current project. It was our objective to 
improve the therapeutic potential of CMCs used for cell therapy by expression of hTERT. 
Despite the negative results observed in hTERT overexpression of CMCs in this study, 




CLONOGENIC CARDIAC MESENCHYMAL CELLS FOR CELL THERAPY 
Introduction 
Clonogenicity, a known stem cell characteristic [69, 70], is the ability of a single 
cell to survive and expand into a large colony of monoclonal cells and retain self-renewal 
qualities [71]. The cloning technique was developed in the 1950s [72] and was used to 
examine the effects of radiation on cells [73, 74]. While other cells can proliferate, 
clonogenic cells must first survive the stress of self-preservation without becoming 
senescent or dying and then maintain the ability of continued proliferation. Later, 
Barrandon and Green classified 3 types of colonies formed by cloning which were termed 
holoclones, meroclones and paraclones using keratinocytes [75]. These classifications are 
derived from cells within the parent population that have different proliferative capacities. 
Holoclones form large, rapidly proliferating colonies with less than 5% of the colonies 
terminally differentiating. Paraclones have limited growth and form small, terminally 
differentiated colonies. And finally, Meroclones form both proliferating and terminally 
differentiated colonies. In the current study, we performed a limited dilution and cloning 
cylinder assay, similar to that described in Puck, Marcus & Cieciura ’s seminal paper [72], 
to select out individual colonies that had varying capacity to grow and survive. The limited 
dilution technique selected clones that would most appropriately be deemed as a 
Meroclone. Then, we performed the cloning cylinder assay and isolated clones from the 
Meroclone, separating them into either Holoclone or a Paraclone colonies, the difference 
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being undefined. By definition, some clones will be more robust than others which we 
believe could provide a method of teasing out more resilient, proliferative cells residing in 
the human CMCs.  
Due to the inherent qualities of clonogenicity and our interest in telomerase, we 
initially believed that cloning would select out telomerase-expressing human CMCs. 
Telomerase is a holoenzyme consisting of a cellular reverse transcriptase (TERT, 
telomerase reverse transcriptase) capable of preventing telomere attrition through de novo 
addition of TTAGGG repeats onto the chromosome ends, called the telomere, by using an 
associated RNA subunit as a template (TERC, telomerase RNA component) [76]. It has 
been found by Blasco’s group that increased TERT expression positively correlates with 
clonogenic potential making it possible for the TERT-expressing CMCs to have a 
predisposition to survive the cloning assay [76]. However, we found that human clonogenic 
CMCs did not have detectable expression of hTERT, which was consistent with our 
previous hTERT findings in human CMCs.  
Despite the lack of hTERT detection in human clonogenic CMCs, we believed that 
isolated clonogenic CMCs alone would be an interesting target for cardiac cell therapy 
since clonogenic CMCs fundamentally exhibit enhanced survival and proliferation 
characteristics compared to non-clonogenic CMCs (parent). An advantage to utilizing this 
simplified methodology would eliminate the need of genetic modification to bolster CMCs 
for cardiac cell therapy, allowing us to achieve the same goal of improved survival and 
proliferation of CMCs in an unbiased approach. To our knowledge, this was the first time 
a clonogenic assay was used to select proliferative, resilient rat CMCs for cardiac cell 
therapy.  
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Although clonogenicity itself is a differentiating characteristic, because of the 
expected variability between isolated CMC clones (i.e. holocone, paraclone or meroclone) 
we further screened clonal rat CMCs. The initial screening tested the resistance of 
clonogenic rat CMCs against oxidative stress. Oxidative stress resistance was selected as 
characteristic because it is known that the environment of the ischemic heart contains high 
levels of reactive oxygen species (ROS) [77], where transplanted rat CMCs would be 
required to survive. Zweier et al. performed several studies measuring free radicals in the 
ischemic heart using electron paramagnetic resonance spectroscopy directly measuring 
free radical generation in perfused rabbit hearts [78, 79]. It was found that the total free 
radical concentration of the control was 4.7 ± 0.5 µM; after 10 minutes of ischemia 
concentration was 6.1 ± 0.4 µM, and after 10 seconds of reperfusion the concentration was 
11.4 ± 0.6 µM. While this free radical increase was observed during ischemia and 
reperfusion, the duration of ischemia and reperfusion differs from a chronic 
ischemia/reperfusion model. However, more recent studies performed by Hill and Singal 
have consistently provided substantial evidence that oxidative stress is increased in heart 
failure following myocardial infarction and contributes to development and progression of 
the disease [80, 81], thus supporting the concept to investigate oxidative stress resistance 
of clonogenic rat CMCs. 
Furthermore, one of the major problems identified with the efficacy of cell therapy 
is insufficient resistance of transplanted cells to oxidative and inflammatory stresses 
leading to poor survival. To investigate this, Zeng et al. pre-treated human umbilical cord 
derived mesenchymal cells (HUCMC) with edaravone and diethyl maleate and observed 
an increased resistance to oxidative and inflammatory stress and a greater amelioration of 
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hepatic injury compared to untreated HUCMC in an acute liver failure model in mice [82]. 
Of additional interest, it has been shown that oxidative stress-induced cells secrete more 
exosomes [77], which some believe to be implicated in ventricular functional improvement 
of the infarcted heart. If oxidative stress induces the release of therapeutic exosomes from 
rat clonogenic CMCs and these CMCs are also resistant to the oxidative stress, this would 
result in prolonging the efficacy of cardiac cell therapy. Interestingly, we discovered rat 
CMC clones that had a range of resistance to oxidative stress compared to the parental rat 
CMC population. We selected the three most and least resistant individual colonies 
(holoclones & paraclones), a batch of mixed clonogenic rat CMCs (meroclone) and 
parental rat CMCs for further experimentation. It is also possible that oxidative stress 
resistance in vitro has no correlation in vivo, making this selection process somewhat 
arbitrary. 
Since many factors contribute to cell death outside of the lack of oxygen in the 
ischemic zone, we performed an additional screening of the rat CMC clones. Other 
contributors of cell death include deprivation of: nutrients, growth factors and survival 
factors. An interesting study in 2005 compared the effects of hypoxia and serum 
deprivation on bone marrow derived mesenchymal stem cells [83]. It was found that in all 
cases, serum deprivation resulted in a greater level of caspase-3 activity and more apoptosis 
than mesenchymal stem cells treated with hypoxic conditions. These results suggest that 
mesenchymal stem cells are far more sensitive to nutrient deprivation than reduced oxygen 
in vitro. They also performed a combined treatment of hypoxia and serum deprivation on 
mesenchymal stem cells and observed a modest additive effect on apoptosis and caspase-
3 activity. Therefor in the current study we investigated if there was a correlation between 
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the results we observed in oxidative stress resistance and serum starvation in clonogenic 
rat CMCs.  
Because we were selecting for proliferative rat CMCs, we calculated the growth 
rate of individual rat colonies. If resistance to oxidative stress or serum starvation is found 
to be important in vivo, then it is possible that growth rate could affect the composition of 
the parental CMCs that had previously shown to improve ventricular function [21]. For 
example, if clonogenic CMCs that are less resistant to oxidative stress do not improve 
ventricular function and have a faster growth rate compared to more resistant CMC clones, 
then it is possible that the parental CMCs have a larger concentration of cells that do not 
improve cardiac function, which could aid in explaining the low survival rate [23]. This 
would support the hypothesis that a subpopulation of CMCs exist that has a greater 
therapeutic efficacy.  
  In consideration that the therapeutic effects of cardiac cell therapy may be a result 
of paracrine stimulation, we also collected conditioned media from each of the selected 
CMC clones to test the stimulatory characteristics of the paracrine milieu released from 
each clone. In an interesting study in Nature Medicine, conditioned media from Akt-1 
overexpressed mesenchymal stem cells (MSC) was collected and injected into the infarcted 
rat heart [84]. Compared to media collected from MSCs transduced with GFP, the Akt-1 
overexpressed MSC conditioned media significantly reduced the size of the infarct. The 
same group saw the same benefit by transplanting Akt-1 overexpressed MSCs into the 
infarcted heart, supporting the possibility that paracrine stimulation is the source of action 
of cardiac cell therapy. While ventricular function is not addressed in this study, the 
reduction of infarct size warrants testing of conditioned media collected from clonogenic 
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CMCs. Finally, we also examined various cell markers with quantitative RT-PCR to 
discern any potential similarities between the selected CMCs. 
In the current study, we also performed an in vivo experiment to compare 
ventricular functional improvement resulting from treatment of chronically infarcted rat 
hearts with either mixed clonogenic CMCs, Parental CMCs or PBS. Echocardiography was 
performed prior to occlusion, before transplant and 30-days after transplantation. After the 
30-day echocardiography was completed, we then performed hemodynamics and 
euthanized the rats per the approved IACUC protocol.  
We postulated that survival, proliferation and paracrine secretion would be 
markedly enhanced in mixed clonogenic CMCs and result in a significant improvement in 
ventricular function when transplanted into the chronically infarcted rat heart. Our results 
reveal significant cardiac functional improvement in rats treated with unsorted, parental 
CMCs, but it was found that rats treated with mixed clonal CMCs had no significant 
functional improvement. Furthermore, we observed that the mixed clonal CMCs from the 
selected rat were less resistant to oxidative stress, less resistant to serum starvation and 
produced a less stimulatory conditioned media compared to the unsorted, parental CMCs. 
These findings revealed that there are clonal CMCs within the parental CMCs that alone 
have reduced therapeutic value. Additionally, there is an implication of a positive 
correlation between our in vitro and our in vivo results. It is possible this correlation may 
pinpoint clonal CMCs within the parental CMC population that provide the therapeutic 
benefits of cardiac cell therapy. If CMC clones are discovered that have a greater 
therapeutic advantage, we can then look for unique identifying markers that enable us to 
more quickly harvest the beneficial CMCs in the future. 
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Materials and Methods 
Explanting CMCs 
To explant CMCs, we used the methodology previously described in the TERT 
experiments. Briefly, cardiac tissue was finely minced and then digested. The digested 
tissue was plated on a 100mm dish and allowed to adhere to the plate. We then harvested 
cells that grew out from the tissue on the plate which we used for these experiments. A 
similar methodology was used for CMCs harvested from rat tissue. Rat tissue was also 
incubated in complete media, but the media differed in composition. 
Rat CMC complete media contained: Ham’s F12 (Gibco) with 10% FBS 
(Seradigm), 5% Horse Serum (Gibco), 10ng/ml bFGF (Peprotech), 0.005 U/ml human 
erythropoietin (Sigma), 0.2 mM L-Glutathione (Sigma), 50 µg/mL Porcine gelatin 
(Sigma), 10 ng/mL Leukemia Inhibitor factor (Millipore) and 100 U/mL Penicillin-
Streptomycin (ThermoFisher).   
 
Clonogenic Assay 
Explanted rat and human CMCs were grown to ~90% confluence and then 
passaged. Plates were washed with PBS and then TrypLE Express (ThermoFisher) was 
added to the plate. Plates were then incubated for 2-5 minutes at 37 oC in 5% CO2. A pipet 
was used to add CM and remove the media from the plate. The mix was transferred to a 
conical tube and then plunged with the pipet to help breakdown the remaining bonds 
between the cells. The mix was centrifuged at 900 g for 3 minutes. The supernatant was 
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removed and the cells were resuspended in 10 mL CM. Using a hemocytometer, the cell 
concentration was counted to determine the number of cells per mL.  
The cloning density was established by performing a limited dilution technique 
[85]. Briefly, 1 mL of the resuspension was added to 9 mL of fresh CM in a separate conical 
tube and mixed well to provide a 1/10 dilution. This was repeated with each subsequent 
dilution to achieve a 1/100, 1/1000 and 1/10000 dilution. Cell dilutions were plated on 
100mm plates and incubated at 37 oC in 5% CO2, allowing single cells to expand to large 
colonies, changing CM every 2-3 days. It was found that diluting the cells to 1000 cells per 
100mm was the optimal number of cells for the cloning technique. Going forward, only 
1000 cells were plated on a 100 mm plate to achieve the results of limited dilution. 
Colonies formed were harvested using two separate methods (Figure 20). The first 
method was the mixed clonogenic population in which we allowed the plated cells that 
formed colonies to fully propagate the 100 mm dish. This dish consisted of all the cells that 
successfully formed colonies. We then continued to expand these cells and deemed them 
the “mixed” clonogenic CMCs. The second method was to isolate individual colonies 
formed from the clonogenic assay using a cloning ring technique [85].   
To do this, individual colonies were identified using microscopy by marking the 
colony location and borders on the underside of the plate with a marker. Then we coated 
the edge of autoclaved glass rings with sterile vacuum grease (Dow Corning) and then 
pressed the greased edge firmly down on the plate so that it surrounded an individual 
colony (Figure 20). This was repeated for 20-30 colonies. The media within the rings was 
aspirated and the colonies harvested by washing with PBS and treating with TrypLE 
Express (as previously described). Cells within the rings were transferred to their own well 
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to continue expansion. Upon expansion, each surviving colony received an ID. All rat 
colonies were photographed to compare morphology between individual colonies. 
Additionally, cloning efficiency was calculated by (# of cells counted/(Volume 
plated*dilution of the volume))*100 to achieve the value for Colony Forming Units (i.e. 
the percentage of cells plated that form a colony). Furthermore, colonies were separated by 
size: Small (3-20 cells), Medium (21-50 cells) and Large (>50 cells) using a previously 





Figure 20 – We performed cloning in two different ways. First, we performed a serial dilution 
to identify the number of cells required for cloning. It was found that 1000 cells plated on a 
100 mm dish was ideal for the cloning technique. Then, we had either Mixed Colonies or 
Single Colonies. For the Mixed Colony, or Meroclone, we plated 1000 cells and then allowed 
the surviving colonies to expand to confluence. For the single colonies, clones were grown 
and then a glass cloning cylinder coated with silicone vacuum grease was used to trypsinize 
and separate the colonies. 
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Oxidative Stress by DMNQ 
To test resistance of oxidative stress on CMC clones, 1x104 cells from each clone 
isolated from the parental CMCs, the mixed clonal CMCs and the parental CMCs were 
plated in quadruplicate on 96-well cell culture plates. DMNQ was added to complete media 
to a final concentration of 1.5 µM (per the determined IC50 concentration). The next day, 
PrestoBlue (Invitrogen) was used following the manufacture’s protocol and viability of the 
CMCs was measured by absorption at Ex/Em 560/590 nm on a Biotek Synergy system. 
The results were graphed as a percentage of the 0.0 µM well to determine the percentage 
of remaining viable cells.  
 
Population Doubling Time 
Population doubling time was performed using a similar strategy used in the TERT 
project. Selected clonogenic CMCs were grown to 90% confluence and then passaged (as 
previously described). After resuspension of the pellet of cells, CMCs were counted using 
a hemocytometer (Bright-Line). After counting, 1x106 CMCs were plated on 100mm 
dishes. This was repeated three times. To calculate doubling time, the number of CMCs 
counted was divided by the number of cells plated, then the number of days between 
passaging was divided by this number to provide the number of days it takes to double. 






Serum Deprivation Assay  
 We then wanted to test the clonogenic CMC’s resistance to nutrient deprivation. 
For this protocol, we plated 1x105 cells in 6-wells of a 6-well plate and allowed them to 
adhere to the wells overnight. The next day, 1 well of cells was passaged and counted with 
a hemocytometer to verify accuracy and efficiency of cells plated per well. In 3 of the other 
wells, the media was changed to basal media. The remaining well was maintained in CM. 
Cells were incubated in the basal media at 37 oC in 5% CO2 for 3 days. Cells were then 
passaged and counted using a hemocytometer in triplicate. The average number of cells 
surviving were compared between clones. 
 
Conditioned Media Production 
 To examine the paracrine milieu produced by the clonogenic cells, we plated 1x106 
of each of the selected clones on a 100mm plate. 24hr later, the media was aspirated from 
the plate and the plate was washed with 1X PBS. Then, 5mL of basal media was added to 
each plate. Cells were incubated at 37oC in 5% CO2 for 24 hours. The media was then 
harvested and placed in a 15mL conical tube and labelled respectively. We performed a 
bicinchoninic acid assay (Pierce), following the manufacturer’s protocol, to determine the 
protein concentration of the conditioned media to verify that there was no significant 
difference in concentration of media produced. Media was stored at 4 oC for later use. 
 
Endothelial Tube Formation Assay  
An Endothelial Tube Formation Assay (Invitrogen) was performed per the 
manufacturers protocol. Briefly, cryopreserved Human Umbillical Vein Cells (HUVEC)  
 60 
cells were plated in a 75 cm2 culture flask and allowed to expand to ~80% confluence 
(about 5-6 days) in EBM-Plus media (Lonza). Geltrex (Gibco) was then thawed overnight 
on ice in the 4 oC refrigerator. The next day, 100-150 µl of Geltrex was added to each well 
of a 24-well plate and incubated at 37 oC for 30min to allow it to solidify. After 30 minute, 
8x104 cells suspended in 250 µl of media were added to each well. The media used for 
resuspension of HUVECs included Complete Media as a positive control, F12 basal media 
(Gibco) as a negative control and media from each of the selected clones. After plating the 
cells on Geltrex-coated wells, the cells were incubated at 37 oC in 5% CO2 for 4 hours. 
Photos of tube formation were taken using an Epifluorescence microscope. Tube formation 
was assessed by counting the number of tubes formed in four fields to arrive at the mean 
tube formation stimulated by the respective media.  
 
HUVEC Migration Assay  
 To test migration, 1x104 HUVEC cells were plated on Boyden chambers containing 
transwells with 8 µm pore size (Corning). After 24 hours, the media in the upper chamber 
was replaced with non-supplemented, serum-free Ham’s F12 media (Gibco) and the 
bottom chamber was replaced with either: Ham’s F12 media (Gibco) containing only 2% 
FBS (Seradigm) as a positive control; Ham’s F12 basal media as a negative control; and 
conditioned media from the selected colonies for the experimental groups. This was 
performed in duplicate. After 24 hours, cells that migrated to lower surface of the transwell 
membrane were fixed with 3.7% formaldehyde for 10 min. Cells remaining in the upper 
chamber were removed using a cotton tip. Fixed cells were permeablized with 0.25% 
Triton X-100 in 1X PBS for 10 min and then incubated with 50ug/ml of propidium iodide 
 61 
solution for 10-15 min. Images were taken using the EVOS FL Cell Imaging System (Life 
Technologies). Migrated HUVECs were quantified. 
 
Quantitative PCR Analysis 
mRNA was harvested from cells, treated with DNase (Qiagen) and purified using 
the RNeasy Kit (Qiagen) following the manufacturers protocol. cDNA was synthesized 
from the mRNA using the AffinityScript qPCR cDNA Synthesis Kit (Agilient). qPCR 
analysis was then performed on samples in duplicate. The human primers used in this study 
were previously described in the TERT study. The rat primer pairs used include:  
Rat Primers 
Marker Primers 
Tert AGCCTTTCTCAGCACCCTGGTC, GCCGGTCTCCACAGGGAAGT 
αSma AGAAGCCCAGCCAGTCGCCAT, CTGCGCTTCGTCCCCCACAT   
Sm22α AGGTGCCTGAGAACCCGCCC, GCCGGGGTCGCCCATAGC 
Thy1 GGGTGCAGCAACCAGAGGCG, AAGGTTGACGCGGGAGCGG 
Fsp1 GGCGAGACCCTTGGAGGAGG, TCCGGGGCTCCTTATCTGGGC 
Ddr2 CCATGCAGGGGGTCATGGCA, TGCCCAGCGGGTGCATTGTA 
Vegf AAAACACAGACTCGCGTTGC, ACTCCCTAATCTTCCGGGCT 
Kdr AAAGAGAGGGACTTTGGCCG, GTCGCCACTTGACAAAACCC 
Tnnt2 AAGCTCTGTTCCTTGCCTGTGC, CGTGGTGTGGGCATAGGGGT 
Myh6 GCGGGCCAAGAGCCGTGAC, GCGAGGCTCTTTCTGCTGGACAG 
18S GGAAGGGCACCACCAGGAGT, TGCAGCCCCGGACATCTAAG 
Table 2: This table provides a detailed list of primers designed for rats and their specific bases 
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Results were analyzed using SDS 2.4 software. Dissociation curves were compared 
to controls for accuracy and CT values were compared among duplicates. If dissociation 
curves did not align with the positive control, the results were deemed as undetected. If CT 
values were dramatically different between duplicates, the experiment was repeated for 
validation. 
 
Experiment Myocardial Infarction and Cell Injection   
This portion of the study was performed in collaboration with Dr. Xian-Liang Tang. 
The methods were like those described previously (Tang et al., Circulation 2010). Female 
Fischer 344 rats (3-4 months of age) were anesthetized with ketamine (37 mg/kg) and 
xylazine (5 mg/kg), intubated, and ventilated with a rodent respirator (Harvard Apparatus). 
Anesthesia was maintained with 1% isoflurane inhalation and body temperature was 
closely monitored and maintained at 37 °C with a heating pad. After administration of 
antibiotics, the chest was opened and the heart exposed. All rats underwent a 2-hr occlusion 
of the left anterior descending coronary artery followed by reperfusion. Thirty days after 
surgery, the animals were randomly allocated to vehicle control group or wild-type CMC-
treated group or mixed clonogenic CMC-treated group. Rats were reanesthetized, the chest 
was reopened, and rats received 6 intramyocardial injections of either vehicle, wild-type 
CMC, or clonogenic CMC (1x106 cells suspended in 300 µL of PBS, 50 µL administered 
in each injection) around the infarct borders using a 30G needle. Rats were euthanized 35 
days after injection.   
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Echocardiography and Hemodynamic Measurement and Analysis 
These experiments were performed in collaboration with Dr. Xian-Liang Tang. 
Serial echocardiograms were obtained at baseline (three days before coronary artery 
occlusion), 30 days after MI (before treatment), and 35 days after treatment using 
Vevo2100 Imaging System equipped with a 20 MHz transducer. Before echocardiography, 
rats were lightly anesthetized with 3% isoflurane. The anterior chest was shaved and the 
animals placed in the left lateral decubitus position. A rectal temperature probe was 
inserted, and the body temperature carefully maintained between 37.0 °C to 37.5 °C with 
a heating pad throughout the study. Anesthesia was maintained with 1% isoflurane 
inhalation. The parasternal long-axis and parasternal short-axis views were used to obtain 
2D and M-mode images for the measurement of the LV mass, LV wall diastolic and 
systolic thickness of the interventricular septum (IVSd and IVSs, respectively) and 
posterior (PWd and PWs), Infarcted and posterior LV wall thickening fraction (IWThF and 
PWThF), end-diastolic and end-systolic volume (LVEDV and LVESV), stroke volume 
(SV), cardiac output (CO), ejection fraction (EF), and fractional area change (FAC). All 
measurements were performed in a blinded fashion per the American Society for 
Echocardiology, and averaged over 3 consecutive cardiac cycles. 
The hemodynamic studies were performed 35 days after treatment, just before 
euthanasia. Rats were anesthetized with ketamine (37 mg/kg) and xylazine (5 mg/kg), 
intubated, and mechanically ventilated.  Anesthesia was maintained with 1% isoflurane 
and the core temperature kept at 37.0 °C with a heating pad throughout the study.  A 2 F 
microtip pressure-volume (PV) catheter (SPR-869, Millar Instruments) was inserted into 
the right carotid artery and advanced into the LV cavity.  The right jugular vein was 
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cannulated for fluid administration.  After 20 min of stabilization, the PV signals were 
recorded continuously with an ARIA PV conductance system (Millar Instruments) 
coupled with a Powerlab/4SP A/D converter (AD Instruments), stored, and displayed on 
a personal computer.  PV relations were assessed by transiently compressing the inferior 
vena cava with a cotton swab.  Parallel conductance from surrounding structures were 
calculated by injecting a small bolus of 15% NaCl through the jugular vein. 




Isolation of Clonogenic Cells 
 We successfully isolated 23 clones from human CMCs and 20+/- clones from 
CMCs of three different rats. A Mixed Clonal population was created in all three rats. 
Photographs were taken at different time points throughout the cloning process (Figure 21). 
All surviving clones were expanded and photographed so that morphology could later be 
compared. Then, clonogenic CMCs were passaged and suspended in freezing media 
containing 10% DMSO and then placed in a CoolCell (VWR) in the -80oC freezer. 24 
hours later, the frozen cells were transferred to liquid nitrogen and thawed as needed.  
The efficiency of our cloning process was determined by plating 1000 cells on a 
100 mm dish. We allowed the colonies to grow 7-10 days prior to fixing them with 3.7% 
formaldehyde and stained them with crystal violet. We counted the colonies and 










Figure 21 – This figure illustrates the cloning technique. We started with the Parent CMCs, 
freshly explanted from the tissue. Cells were diluted so that single cells adhered to the plate. 
Only the clonogenic cells proliferated into colonies, while non-clonogenic cells die. The 
colonies are either allowed to expand to a Mixed Clone plate or individual colonies were 







medium or large, we concluded that our efficiency was around 8% (Figure 22). Our 
efficiency was found to be consistent with other studies [87].  
 
Human Clonogenic CMC Gene Expression 
 As previously stated, it was believed that if a sub-population of cells expresses 
 
Figure 22 - Cloning efficiency was then calculated by plating 1000 cells and allowing them to 
form colonies. Colonies were then fixed to the plate with 3.7% formaldehyde and stained with 
crystal violet (left). Colonies were quantified by size in three rats and then provided as a 
Colony Forming Unit mean. Colonies were divided into sizes S (3-20 cells), M (21-50 cells) 
and L (>50 cells). Clones selected by the cloning cylinder were primarily M+L in size. 
 
Figure 23 - Human Clonogenic CMCs from a single patient were analyzed using quantitative 
RT-PCR. hTERT was not detected among the human clones (left). C-kit was detected at 
varying levels among human CMC clones (right). Only 23 clones were investigated for 
hTERT, whereas 3 additional clones were investigated for other markers.  
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TERT it would likely be represented in the clonogenic population. Consistent with our 
previous study, we did not detect hTERT in human clonogenic CMCs (Figure 23). Other 
markers confirmed that these clones represented unique populations and are from a 
mesenchymal stromal cell lineage (Figure 23, Figure 24, Figure 25).  
Since hTERT was not detected in the human clones, our testing of clonogenic cells 
shifted to rat isolates. Survival of the clonogenic assay alone is a selection for CMCs with 
enhanced survival characteristics. For that reason, we expedited an in vivo study of 
clonogenic CMCs in the rat model. Thus, we performed an in vivo study and in vitro studies 
in rat clonogenic cells simultaneously. 
 
Resistance to Oxidative Stress Induced by DMNQ in Rat Clonogenic CMCs 
 The first of our in vitro experiments in the rat clonogenic CMCs was to test their 
resistance to oxidative stress. We initially induced oxidative stress by treating cells with 
varying concentrations of H2O2. However, we found the results to be inconsistent among 
the replicates of the same cell line. Therefore, we used a cell-permeable, non-alkylating 
redox cycling quinone called 2,3-Dimethoxy-1,4-naphthoquinone (DMNQ). DMNQ 
works by generating intracellular reactive oxygen species. We found our results with 
DMNQ to be far more consistent among replicates providing a higher level of confidence 
in the data.  
Among rat clonogenic CMCs, it was found that clones have varying levels of 
resistance to oxidative stress induced by 1.5 µM DMNQ (Figure 26). Compared to the 
parental CMCs (non-clonogenic cells), some clones exhibited significantly higher 




Figure 24 – Quantitative RT-PCR was performed on 26 different clones and compared to 
mRNA harvested from the whole heart. A. Varying levels of fibroblast markers were detected 
among clones. #6 seems to have a high expression compared to the others CMC clones. B. 
Endothelial cell markers were expressed at low levels compared to the whole heart. C. 
Smooth muscle cell markers are also variable and appear to express higher levels than the 








the mixed clonogenic CMCs from the R18 rat, which also happened to be the clonogenic 
CMCs selected for the in vivo study, had a significantly lower resistance to oxidative stress 
compared to the parent CMCs. The R19 and R20 rat mixed clones were significantly more 
resistant, suggesting that the mixed cloning technique may not be a reliable method of 
selection. The R18 rat results will be discussed in more detail later in this this study. We 
then selected the three most resistant and three least resistant clones from each rat for 
further experimentation. Although clones were selected as “least resistant,” this did not 
always mean clonal CMCs were less resistant to oxidative stress than parental CMCs.  
 
Growth Rate in Rat Clonogenic CMCs 
 After selecting the three clones that were most and least resistant to oxidative stress, 
 
Figure 25 - A. Pericyte marker (left) and progenitor cell marker (right) were detected at very 
low levels in clonogenic CMCs. B.CD146, another progenitor marker, was also expressed at 





we calculated the growth rate of the selected CMCs over three passages. Generally, there 
was no difference in the growth rate observed between clones. Although, one of the most 
resistant clones in the R18 rat and the R20 rat had a significantly slower growth rate than 
the parental CMCs (Figure 27A). It was also observed that in many cases, the lease resistant 
clones trended toward having a faster growth rate. This is important because if oxidative 
stress resistance correlates with in vivo functional improvement, then this would mean that 
cells with the least resistance make up a larger percentage of the parental population 
 
Figure 26 - Rat clones from three different rats were subjected to oxidative stress induced by 
1.5 µM DMNQ. Each figure is labelled in the top left corner respectively, they include R18, 
R19 and R20. There is a variety of resistance to oxidative stress. The clones circled were 
selected for additional experiments. These clones represent the 3 most and least resistant 
CMC colonies. In the R18, the Mixed Clone and Parental Clone were used for in vivo 
experimentation. 
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because the calls can proliferate at a greater rate. Therefore, only a small fraction of CMCs 
would exist that result in the therapeutic benefits observed implying that transplanting a 
greater quantity of only this subpopulation of cells would result in a greater functional 
improvement. 
 
Serum Deprivation in Rat Clonogenic CMCs 
 Next, we subjected the selected clones to serum starvation to determine if resistance 
to oxidative stress correlated with survival to nutrient deprivation.  It was found that 
selected clones had similar viability after being subject to serum deprivation for 3 days 
(Figure 27B). It was also found that the mixed clonal CMCs from the R18 rat were 
significantly more sensitive to serum starvation than the parental CMCs, but this seemed 
coincidental. There was no noticeable viability trend among the clonal populations. In fact, 
one of the least resistant clones in the R18 rat was significantly more sensitive to serum 
starvation. At the same time, one of the least resistant clones in the R19 rat was significantly 
less sensitive to serum starvation.  
 
Gene Expression in Rat Clonogenic CMCs 
 Quantitative RT-PCR was performed on the selected clones to identify any 
potential trends between populations of clonal CMCs. It was found that in every case, the 
least resistant CMC clone selected from each rat expressed no smooth muscle cell markers 
(Figure 28) and very little fibroblast markers compared to other CMC clones (Figure 29, 
Figure 30). It was also found that all of the least resistant CMC clones among all rats had 






Figure 27 - In both A & B, the Oxidative Stress Resistance Level (OSRL) is indicating the 
level of resistance to oxidative stress by which the clone was selected. Up = Most resistant, 
Down = Least A. Population doubling (growth rate) was tracked over three passages in the 
selected clones from all 3 rats (R18, R19, R20). The R18 #3 clone and the R20 #4 clone 
doubled significantly slower than the parental cell line. B. Selected clones from all three rats 
were also subjected to serum deprivation. After 3 days of serum starvation, the remaining, 
viable cells were quantified by counting the number of cells using a hemocytometer. In the 
R18 rat, the #17 and & Mixed clone were significantly less resistant to serum starvation. 




Additionally, the mixed clonal CMC populations had similar expression and in some cases 
was very similar to the least resistant CMC clones. Other CMC clones had varying levels 
of expression with no apparent trend. If resistance to oxidative stress does correlate with 
ventricular functional improvement, this may help us to define the specific sub-population 
of CMCs that provide therapeutic benefit. If we can identify a unique set of markers with 
the most resistant CMCs, this would eliminate the need for the arduous selection process. 
 
Endothelial Tube Formation Assay with CMC Conditioned Media 
 After culturing one million clonal CMCs in basal media overnight, the conditioned 
media was collected. This was performed in each of the selected CMCs from all three rats. 
The conditioned media from the R18 rat was used in an endothelial tube formation assay 
to determine if any of the CMC clones produced a more stimulatory conditioned media. 
Because of the sensitivity of the HUVEC cells, this assay was performed multiple times. 
We first examined the quantity of protein in the conditioned media to verify that the 
differences observed were not simply a result of a variation in the quantity of factors 
released from the CMCs. Our BCA assay revealed that there was no significant difference 
in protein concentration between the conditioned media produced by each CMC clone 
(Figure 31).  
Once no difference in protein concentration in collected media was confirmed, we 
proceeded forward to test stimulation of endothelial tube formation using the conditioned 
media (Figure 32). Most of the clonal CMCs did not cause a significant increase or decrease 
in endothelial tubes formed, but this lack of significance may have been a result of too few 





Figure 28 - Smooth muscle markers were variable among CMC clones in 3 rats (R18, R19 & 
R20). The least resistant CMC clone in each rat (circled) consistently had incredibly-
low/undetectable levels of smooth muscle markers. Oxidative Stress Resistance Level 
(OSRL) is indicating the level of resistance to oxidative stress by which the clone was 















Figure 29 - Fibroblast markers were variable among CMC clones in all rats (R18, R19, R20). 
The least resistant clone in each rat (circled) consistently had similar detection of Thy1. 
Unlike fibroblast markers Thy1 of DDR2 (Figure 30), Fsp1 had variable levels of detection. 
Oxidative Stress Resistance Level (OSRL) is indicating the level of resistance to oxidative 













Figure 30 – The least resistant clone in each rat (circled) consistently had similar detection of 
DDR2. Angiogenic marker VEGF was relatively similar among all clones, but the least 
resistant in all rats (circled) had a lower detection of VEGF. Oxidative Stress Resistance 
Level (OSRL) is indicating the level of resistance to oxidative stress by which the clone was 



















cause significantly more endothelial tube formation than the parental CMCs (Figure 33). 
Of added interest, the Mixed CMC Clone was close to being significantly less stimulatory. 
For that reason, we repeated the experiment specifically looking at the Mixed Clone 
compared to the parental cell line. It was found that the Mixed Clone did indeed 
significantly stimulate the formation of fewer endothelial tubes (Figure 34). This again 
suggests that the Mixed Clonal CMC population in the R18 rat are CMCs. The results 
indicate that subpopulations do exist in the CMCs that have differential paracrine milieu, 




Figure 31 - Conditioned media was collected from each of the selected R18 CMC clones. The 
protein concentrations of the collected conditioned media were measured using a BCA assay. 
No significant difference in concentration was detected between the conditioned media from 
the selected CMC clones. Oxidative Stress Resistance Level (OSRL) is indicating the level of 






Figure 32 - HUVEC cells plated on geltrex-coated plates were incubated in conditioned 
media from selected CMC clones for 4 hours. Then, representative photos were taken from 
different fields for each well treated with conditioned media, compared to Complete Media 
and Basal Media. These images are representative of the variation of tube formation results 
observed. 
Complete Media Basal Media 
R18 Parent Conditioned Media R18 Mix Clone Conditioned Media 




HUVEC Migration Assay 
To further examine the conditioned media, we performed a Boyden chamber assay. 
We plated HUVEC cells on the semi-permeable membrane of a transwell plate and a tested 
the ability of conditioned media from the R18 selected clones to stimulate migration across 
the membrane. In most cases, there was no significant difference in migration compared to 
the parental CMC conditioned media (Figure 35). The R18 #18 CMC clone conditioned 
media did cause significantly more migration than the parental CMC conditioned media 
(Figure 36). Coincidentally, the R18 #18 CMC clone was also selected as one of the most 
resistant CMC clones. Other conditioned media from the most resistant clones appeared to 
be trending toward having more migration, but it was not significant compared to 
 
Figure 33 - Tube formation was quantified by counting the number of tubes formed in two 
separate fields (n=2). The #8 clone had significantly more tubes formed compared to parental 
media. Basal media is growth factor (GF) free media while Complete Media (CM) had GFs. 
Oxidative Stress Resistance Level (OSRL) is indicating the level of resistance to oxidative 







Figure 34 – The endothelial tube formation assay was repeated. HUVEC media with GF was 
used as a positive control and GF-free media were the negative controls. Mixed CMC clonal 
conditioned media formed significantly less tubes than the parental cell media. In this 
experiment, we analyzed 4 fields per sample (n=4).  
Complete Media Basal Media 
R18 Parent Conditioned Media R18 Mix Clone Conditioned Media 
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parental CMC conditioned media. It was also found that the conditioned media from the 
mixed CMC clones had a similar stimulation for migration as the parental CMC 
conditioned media. This lacks consistency from the other findings in which the parental 
CMC population outperforms the mixed clonal CMCs in the R18 rat. 
 
CMC Clone Morphology 
 While it may have been purely coincidental, we also made note of some interesting 
morphological differences between the clones. It was found that the clones most resistant 
to oxidative stress in each rat had a very similar morphology. These clones were larger, 
rounded and flattened with more surface area in contact with the dish. By comparison, the 
clones with the lease resistance to oxidative stress were elongated and had a narrow spindle 
shape. This may provide a crude method to quickly identify the cells of interest for cell 
 
Figure 35 - HUVEC cells were plated on a transwell plate. Conditioned media from the R18 
selected CMC clones was used an attractant and CMCs were allowed to migrate overnight. 
There was no significant difference among most R18 CMC clones, but the #18 CMC clone 
had significantly more migration. The #3 CMC clone trended toward having more, but lacked 










Figure 36 – HUVEC cells were plated on a semi-permeable transwell plate. The next day, the 
media top well of the plate was changed to basal media and the bottom well was changed to 
the media of interest. Cells were incubated overnight and then fixed with 3.7% formaldehyde, 
stained with Propidium Iodide and then representative images were taken from 4 fields in 
each treatment group (n=4). Cells were then quantified. 
Complete Media Basal Media 
R18 Parent Conditioned Media R18 Mix Clone Conditioned Media 
R18 #3 Clone Conditioned Media R18 #18 Clone Conditioned Media 
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therapy if a correlation can be made between in vitro and in vivo data. 
Transplantation of Mixed Clonogenic CMCs into the Chronically Infarcted Rat Heart  
Female Fischer rats (n=24) underwent ischemia/reperfusion surgery (Figure 38). 
After reperfusion, rats were re-anesthetized and had the treatment transplanted around the 
border zone of the infarcted heart. Treatment included: 1 million R18 Mixed Clonal CMC 
(n=8), 1 million R18 Parent CMC (n=8) or PBS (n=8). CMCs were suspended in 300 µl of 
PBS. 35 days after transplantation, ventricular function was measured and rats were 
euthanized. Mortality within treated rats was very low, only two rats died during this study 
 
Figure 37- Cell morphology images were captured in all clones from all three rats. Shown 
here are the most and least resistant to oxidative stress from the R19 & R20 rats. The quality 
of the R18 photos was poor, so they were not included. Despite that, the most resistant clones 
in all rats had similar phenotypes. The most resistant were very large, flattened cells. When 
compared to known cardiac cell types, the most resistant resembled endothelial cells and the 
least resistant were similar to mesenchymal cells. 
Most Resistant Clone (R19) Most Resistant Clone (R20) 
Least Resistant Clone (R19) Least Resistant Clone (R20) 
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(1 PBS treated rat, 1 Parental CMC treated rat). Upon analyzing echocardiography, it was 
found that rats treated with parental CMCs from the R18 rat exhibited significant 
improvement in ejection fraction and fractional shortening compared to PBS treated rats 
(Figure 39). However, the rats treated with Mixed Clonal CMCs from the R18 rat show no 
improvement in ventricular function. Hemodynamic data varied slightly, showing an 
improvement in end-systolic volume and pressure in the parental CMCs, but oddly did not 
show a significant improvement in ejection fraction (Figure 40). Overall the results show 
a significant, albeit modest, improvement in ventricular function in parental CMCs and no 
change in the Mixed Clonal CMC treated rats. This revealed that there are CMCs that do 
provide a therapeutic benefit and that there are subpopulations of cells that do not provide 
a functional improvement. This implies that there are subpopulations, whether it be a single 
cell type or combination of cell types, of CMCs within the parental CMCs that are more 
 
Figure 38 - This is a graphical representation of the surgical protocol. Female Fischer rats 
received baseline echocardiography. 3 days later they underwent 2 hours of occlusion 
followed by 30 days of reperfusion. Pre-treatment echocardiography was performed and then 
then treatment was administered to the damaged heart. Treatment included: 1 million R18 
Mixed Clonal CMC (n=8), 1 million R18 Parent CMC (n=8) or PBS (n=8). CMCs were 
suspended in 300 µl of PBS. After 35 days, echocardiography was again performed along 
with hemodynamics. 
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therapeutically advantageous. Concurrently, the in vitro findings with the Mixed Clonal 
CMCs from the R18 rat appear to positively correlate with the in vivo results.    
Discussion 
For the first time in our hands, we confirm that unsorted rat CMCs can improve 
cardiac function in the chronically infarcted rat heart. Our data reveals cell therapy using 
mixed clonal CMCs from the R18 rat does not attenuate heart failure in the chronically 
infarcted heart. We also saw that the mixed clonal CMCs from the R18 rat performed 
poorly in vitro. Results show that the R18 mixed clonogenic CMCs were less resistant to 
oxidative stress, less resistant to serum starvation and produced a less stimulatory paracrine 
milieu. In contrast, mixed CMC clones from R19 & R20 rats performed better in vitro 
compared to the R18 mixed CMC clonal population, implying that the mixed clonal CMCs 
are an unreliable source of clonogenic CMCs. Additionally, it was found that individual 
clones in the R18 rat outperformed the mixed clonal CMCs in vitro. Since our in vitro data 
 
 
Figure 39 - Ejection fraction and fractional shortening was found to be significantly improved 
in the parental CMC treated group (white bar) compared to the PBS treated group (green bar). 




for the R18 mixed clonal CMCs correlates with our in vivo data, it supports the rationale 
that transplanting CMCs with “superior” in vitro results would yield a greater improvement 
in ventricular function in the chronically infarcted rat heart.  
Until now, cells transplanted into the heart have been a heterogenous mix, even in 
sorted cells. Heterogeneity is further amplified in co-transplantation studies showing a 
synergistic improvement in ventricular function [25, 88]. The benefit of our approach is 
 
Figure 40 - Hemodynamics data was less convincing than echocardiography, but trended 
toward similar results. End-systolic volume was significantly improved in parental CMC 
treated groups compared to the Mixed clonal CMC treated group. End-systolic pressure in 
Parental CMC treated rats was significantly improved compared to the PBS treated group. 
However, there was no difference in ejection fraction among any groups. 
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that we are reducing CMCs down to a single cell type and expanding more homogenous 
colonies. If we can identify which specific cell type in the CMC population is the most 
advantageous, we can then begin to identify why certain CMCs or combinations of CMCs 
are more valuable for cell therapy.  
 Of course, it is possible that a combination of CMCs is required to improve cardiac 
function. It may be that the heterogenous mix of parental CMCs (or other cells used for 
cardiac cell therapy) is essential to achieve the therapeutic benefits observed. The reduced 
heterogeneity may explain why the R18 mixed clonal CMC population was ineffective. 
However, the argument could be made that mixed clonal CMCs themselves are 
heterogenous CMCs. Although, it is important to recall that the mixed CMC population in 
the R18 rat was less viable than other mixed clonal CMC populations from other rats. The 
individual R18 clones, which make up the mixed population, also had a larger variation in 
resistance. It could be that the R18 CMC clones with significantly less resistance make up 
a greater concentration of the mixed clonal CMC population thereby driving down their 
therapeutic potential.  
Regardless of rejecting our hypothesis, the preliminary results confirm that 
populations of CMCs exist that afford a differential therapeutic potential. The current 
correlation of in vitro and in vivo data is promising and may provide us with the 
methodology to identify sub-populations of CMCs that are responsible for the ventricular 
functional improvement observed. We are currently underway with a secondary in vivo 
study that tests if a clone more resistant to oxidative stress delivers a greater improvement 
in ventricular function compared to a clone with less resistance. Since we saw a variation 
in gene expression, we are also currently performing a microarray of the mRNA to attempt 
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to tease out unique markers that identify the “superior” clones. The outcomes of our 
ongoing studies are sure to address these important questions. 
 89 
CHAPTER IV 
CONCLUSIONS AND FUTURE DIRECTIONS 
 In these studies, our goal was to identify a method of prolonging the therapeutic 
benefit of cardiac cell therapy to generate a greater improvement in heart function. Our 
first solution was to locate CMCs that endogenously expressed telomerase (TERT). We 
also artificially overexpressed TERT in CMCs using lentiviral transduction. In other cell 
types, TERT expression has been shown to immortalize the cells [41, 43, 44] , but 
expression in cardiac mesenchymal cells had not yet been addressed. While we were 
successful in achieving TERT expressing CMCs, we found that TERT expression did not 
immortalize or offer any secondary protective or migratory characteristics in CMCs. We 
concluded that TERT is not singularly responsible for prolonging the proliferation or 
survival of CMCS. In a last-ditch effort, we tried to narrow our search for TERT in CMCs 
by looking for expression in clonogenic CMCs, but expression was again not detected.  
While we believe that the novelty of exploiting TERT for cardiac cell therapy has 
yet to be pinpointed, the premise of clonogenic CMCs has led us to some interesting results. 
In this study, we identified clonogenic sub-populations of CMCs that exhibited survival 
and paracrine characteristics that had potential therapeutic implications. We then show for 
the first time in our hands that we can attenuate heart failure with transplantation of 
unsorted CMCs. We also saw that mixed clonal CMCs with reduced survival and paracrine 
characteristics in vitro correlated with no enhancement of cardiac function in vivo. Results 
confirmed that cells exist in the CMC population that serve little benefit for cardiac cell 
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therapy. This suggested the possibility that clonal CMCs with “superior” characteristics 
would provide an improvement in ventricular function. In fact, we are currently underway 
with another in vivo experiment in rats to support this hypothesis. We are also running a 
Microarray on mRNA harvested from select CMC clones to find any coinciding data that 
would help us determine a marker(s) to quickly identify “superior” CMCs. Evidence of 
finding these unique markers was promising from the gene expression results found in this 
study. 
 If we are successful, “superior” CMCs used for cardiac cell therapy will have been 
identified without prejudice and optimized without the need for exogenous modification 
(i.e. TERT overexpression).  If an improvement in function is observed, we would then 
need to elucidate the mechanism. We would first identify if there was an improvement of 
survival by utilizing the methodology developed in our lab to precisely quantify the 
surviving CMCs [23]. We would also examine if CMCs functionally integrate into the 
damaged myocardium. Although, thus far no cell type has convincingly proven to replenish 
the cardiomyocytes in the heart so it would be unreasonable to expect otherwise with the 
“superior” clonogenic CMCs [89].  
However, it is possible that select clonal populations of CMCs ameliorate cardiac 
function to a greater extent by paracrine signaling [90]. One study has shown that c-kit+ 
sorted cardiac cells (CSC) preconditioned with exosomes released from bone marrow-
derived mesenchymal cells stimulated proliferation, migration and tube formation of the 
CSCs [91]. The researchers also observed a greater improvement in ventricular function 
after transplantation of these preconditioned CSCs into the heart. This suggests the 
possibility that potent paracrine factors released from CMCs could stimulate endogenous 
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CSCs to generate a greater protection and/or improvement of function. In other words, it 
may be possible that the paracrine factors released from certain sub-populations of CMCs 
could provide the optimal support for endogenous CSCs to alleviate pathological 
dysfunction.  If the oxidative stress resistant clonogenic CMCs survive longer, it is possible 
that ROS present in the ischemic heart stimulates a prolonged release of paracrine factors 
and therefore yields a greater functional improvement  [92].  Again, it was previously 
shown by Mohsin et al. that prolonging the survival of transplanted cells resulted in a 
greater improvement of ventricular function [26]. Of course, paracrine stimulation also 
insinuates a mediated immune response which is known to be important in remodeling the 
damaged heart [93, 94].  
 In fact, many believe that the immunologic response may be complemented by cell 
therapy [95]. It has been shown that immune activation is required for the repair of the 
damage by clearing debris and stimulating remodeling of the damaged heart. It is thought 
that immunity aids in providing an appropriate microenvironment for the survival, 
development and function of the transplanted cells. While it has not been unequivocally 
proven, the immune system is also believed to initiate regeneration of the damaged tissue 
dependent upon the availability of progenitor cells. It is possible that there are clonal CMCs 
that provide a more complementary interaction with immunity, which may explain 
variances in outcome that have been observed to this point. By utilizing more homogenous 
“superior” populations of CMCs resistant to stress, we may be able to expose CMCs that 
synergize better with the immune system.  
 If resistance to oxidative stress correlates to improved function, it could also be the 
result of elevated levels of intracellular antioxidants compared to the less resistant CMCs. 
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In muscle-derived stem cells, it was found that antioxidant depletion caused a significant 
reduction is cell survival to oxidative and inflammatory stress [96].  The study also 
discovered a reduced survival of cells transplanted into the infarcted heart and significantly 
less improvement of ventricular function. From what we have found, antioxidants in CMCs 
have yet to be investigated. The mRNA microarray may reveal expression of intracellular 
antioxidants of interest that we could then overexpress to confirm protection of the CMCs. 
Within that realm, it is possible that transplanted CMCs somehow aid in reducing 
oxidative stress on surviving cardiomyotcytes. During ischemia, the cardiac tissue shifts to 
anaerobic metabolism decreasing the pH of the cell [97]. To combat it, the sodium-
hydrogen ion exchanger excretes excess hydrogen ions causing an increase of sarcoplasmic 
sodium. There is also a depletion of ATP which results in a reduction of calcium ion uptake 
by the sarcoplasmic reticulum. This causes an increase in mitochondrial permeability and 
further reduces ATP production. In our model, ischemia is followed by reperfusion which 
restores delivery of oxygen and nutrients for aerobic metabolism and washes out the 
hydrogen ions to restore the extracellular pH. However, reperfusion itself causes injury. 
Some of the causes of reperfusion injury include the generation of ROS, calcium overload 
and an inflammatory response [97]. The ROS can target the L-type calcium channels and 
suppress the calcium ion current [98]. It can also reduce the activity of calcium-ATPase on 
the sarcoplasmic reticulum, shown to affect contractility [99]. ROS has also been shown to 
influence contractility by depressing myofilatment sensitivity to calcium [100]. If the 
transplantation of cells helps to reduce the oxidative stress on the surviving cells, it could 
aid in restoring the appropriate flow of calcium ions and improve contractility of the 
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cardiac cells. This may result in a modest improvement of cardiac function without the 
functional integration of transplanted cells.  
Of course, most of this is conjecture until a correlation between oxidative stress and 
improved ventricular function is found. It is very possible that the results thus far have 
merely been coincidental. It is also possible that we will find that to achieve functional 
improvement we need a combination of cells. It may be that no unique cell type is 
individually important, which would give greater support to the paracrine hypothesis. 
However, our discussion of the various potential outcomes provides a road map of 
different directions this project could take in the future. It is easy to see that there is much 
that can be done to continue exploration of these results. Indeed, it is unknown what the 
future may hold for the project. What is known is that we have observed that a sub-
population of cells within parental CMCs, that alone provide cardiac improvement, 
provided no therapeutic benefit in vivo and correlated with our in vitro findings. Finding 
the reasoning for this difference observed is certain to lead to some incredibly important 
findings for the field of cardiac cell therapy. 
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Starlight Strawberry Festival, Spring 2013 - Current 
 Advertising Design, Internet Marketing, Website Design & Management 
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Kosair Charities, Fall 2014 
 Coordinating a fall fundraiser raising over $3,000 
Children’s Miracle Network, Fall 2012 
 Coordinating a fall fundraiser raising $1,600 
American Red Cross Blood Drive, Fall 2010-2012 
 Coordinated multiple blood drives responsible for bringing in hundreds of donations 
Special Needs, Winter 2005-2011 
 Assist with holiday party management, ornament presentation, and more 
VistaCare Hospice, Spring 2006-Fall 2008 
 Food Drives and created ceramic painting parties to produce gifts for patients 
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